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Abstract 
 
Background and Purpose: The objective of the study was to compare intensity modulated 
radiotherapy (IMRT) and intensity modulated proton therapy (IMPT) for locally advanced 
cervical cancer in terms of dose-volume parameters, dose coverage, homogeneity and 
conformity. Furthermore, to study the effect of reduced margins.  
Study design: External beam radiotherapy planning was carried out for 10 patients with 
locally advanced cervical cancer, out of which 5 recieved treatment for para-aortic lymph 
node involvement in addition to pelvic irradiation. Dose prescription for the PTV was 50.4Gy 
in 28 fractions with a dose coverage criteria set to D98%≥95%. Two sets of treatment plans 
were prepared for both modalities based on different CTV-PTV margins: clinical margin (7 
mm L-R, 10 mm S-I, 15 mm A-P) and reduced margin (7 mm isotropic). The IMRT and 
IMPT plans were generated using the Eclipse treatment planning system (Varian Medical 
Systems, Palo Alto, CA). Dose-volume histograms (DVHs) were analyzed for the PTV and 
various organs at risk (OARs; rectum, bladder, bowel, sigmoid, left, right kidney, medulla, 
cauda equina and pelvic bone). Student’s t-test was used for all statistical comparison.  
Results: The prescription was well achieved with all IMRT and IMPT plans covering 98% of 
the PTV with the 95% isodose. The ratio between IMRT and IMPT was calculated. IMPT 
demonstrated the potential in sparing doses to OARs, where significant differences were seen 
compared to IMRT for many dose-volume parameters (table 5). Concerning the reduced 
margins, increased differences between IMPT and IMRT were seen in the rectum, bladder for 
all parameters and for the low, medium dose region of bowel. For OARs sigmoid and high 
dose range of bowel however, less changes in the IMRT to IMPT dose-ratio was found when 
reducing CTV-PTV margins. Moreover, the same effect was seen for the medium, high dose 
regions of pelvic bone. Importantly, a decent dosimetric gain was also apparent in low dose to 
outer body. A clinically non-significant dosimetric variation was seen for medulla and cauda 
equina. The dosimetric gain was however reduced for kidneys (table 6).  
Lastly, a considerably large reduction in high dose to rectum and bladder was seen for IMRT, 
utilizing smaller margins as compared to clinical margins whereas, a decent dosimetric gain 
was also clearly seen for the sigmoid and bowel, at high dose level (table 8).  
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Conclusions: IMPT has considerable potential to spare the OARs, while maintaining 
excellent planning target coverage, for patients with cervical cancer. Advanced image guided 
strategies and adaptive radiotherapy approaches could open this therapeutic window further.  
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1 Introduction 
Locally advanced cervical cancer is a gynecological cancer which often has a tendency to 
metastasize, primarily through the pelvic lymph nodes and then to the para-aortic LN. Locally 
advanced cervical cancer patients are generally given whole pelvic radiation therapy to limit 
local metastasis in the pelvic area while para-aortic radiotherapy is given to sterilize distant 
metastasis (1, 2). Radiation therapy can be administered externally or internally to the affected 
area. External radiotherapy (EBRT) involves the irradiation of tumour from external source 
whereas internal radiotherapy involves the placement of radioactive source in or in the 
vicinity of the tumour area. The latter technique is known as ‘brachytherapy’. For cervical 
cancer brachytherapy is used in combination with EBRT to deliver a local boost dose to the 
tumour.  This combined radiotherapy is then delivered with concurrent chemotherapy. Such 
protocol is considered as a primary standard protocol for locally advanced cervical cancer 
patients (3, 4) (2).   
Conventionally EBRT is delivered, with high energy photon beams using a four-field box 
technique to achieve local tumour control. However, due to the large field size in the radiation 
portal, rather large volumes of the bowel and rectum have to be included to adequately treat 
the lymph nodes. It is well known that radiotherapy in pelvic area is often associated to many 
complications in normal pelvic organs. Several studies have confirmed the incidences of both 
acute and late gastrointestinal (GI) and genitourinary (GU) toxicities (5, 6) (7). Few studies 
have shown the incidences of acute hematological (HT) toxicities following pelvic chemo-
radiation (4, 5). These substantial risks of acute and late complications have driven the need 
to develop intensity-modulated radiation therapy (IMRT). It has been considered as a 
potential replacement of traditional four-field box technique. IMRT allows the delivery of 
highly conformal dose due to steeper dose gradient to the complex and irregular shape and 
size of the target volume in cervical cancer. IMRT has shown the potential to reduce the 
harmful dose to the healthy surrounding structures without compromising adequate dose to 
the tumour volume (8, 9). Various studies on IMRT to pelvic gynecological malignancies 
have shown the significant reduction in the incidence of acute GI toxicities (10, 11) (12). 
Various studies have also shown the decrease in the incidence of HT toxicities (13, 14). For 
para-aortic LN irradiation, extended field IMRT for cervical cancer has shown the reduction 
in acute and late side-effects (15, 16). Furthermore, IMRT potentially allows dose escalation. 
However, there exists a downside to IMRT in its potential to increase the risks of radiation 
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induced secondary cancers mainly due to two reasons: larger total body dose and higher 
integral dose as larger volume of normal tissues receive low dose (17).  
In the hope of further reducing the radiation induced toxicities in normal organs and avoid the 
chances of having secondary cancer, protons are considered as an attractive replacement to 
IMRT in delivering highly conformal dose to the target coverage and increasing organs at risk 
(OARs) sparing to much further extent (18). The fundamental reasons underlining the benefits 
of protons is due to their physical characteristics like low entrance dose, flat and uniform 
spread-out Bragg peak (SOBP), finite range of particles and sharp distal dose fall-off (19). 
Few studies have looked into the use of proton therapy in cervical cancer patients and have 
concluded the excellent dosimetric advantages in sparing dose to OARs (20, 21). In proton 
therapy, dose can be delivered using passive scattering techniques and active spot scanning 
techniques. Active spot scanning is also known as intensity modulated proton therapy 
(IMPT). It is this technique which reduces the chances of radiation induced secondary cancer 
because of no production of neutrons and hence, less scattered dose to patients (17).  
Accuracy is a prerequisite to deliver high quality radiotherapy. Factors like range and, energy 
uncertainties affect delivery of radiation therapy and should be taken into account during the 
treatment planning procedures. Considering the fact that pelvic organs are naturally prone to 
positional and volumetric changes over time (22), such variations should be accounted for. 
Also, various studies have demonstrated the existence of correlation between bladder and 
rectum filling on uterus and cervix motion, respectively (23). As a result, it changes the shape 
and position of cervix-uterus target volume. Figure 1 shows the variable bladder filling in a 
cervical cancer patient. The use of a drinking protocol during the treatment course to 
reproduce bladder filling will minimize the impact of bladder filling on cervix-uterus motion 
(24, 25). Therefore, depending upon the pre-treatment established co-relation between bladder 
filling and inter-fractional cervix-uterus motion suitable margins should be added to 
adequately cover the target volume in cervix-uterus tumour. It has been agreed through 
various studies that the impact of bladder variation on cervix-uterus movement is patient-
specific (26, 27), thus varies from patient to patient. Figure 2 shows the inter-patient variation 
in cervix-uterus motion during treatment course. Moreover, cervix-uterus tumour is known to 
regress during the course of treatment as shown in few studies (28). All the reasons mentioned 
above provides evidence against the usage of clinical recommended population-based margins 
as they unnecessarily includes normal tissues under high dose irradiation for patients with 
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smaller target motion. Therefore, large inter-patient variability in cervix-uterus motion limits 
the benefit of highly conformal treatment techniques (29). This calls for the employment of 
patient-specific total margins around tumour volume to support personalized treatment 
strategies or adaptive radiotherapy (30).  
 
  
Figure 1 Sagittal view of variable bladder and rectum filling CT-scans in week 2 and week 5 during treatment course, 
respectively for cervix-uterus cancer patient. The influence of variable bladder and rectum filling can be seen in the 
change of cervix-uterus position. The above shown images are taken from (31) 
 
 
 
Figure 2 Sagittal cuts of the CT-scans showing inter-patient variability in cervix-uterus motion for two cervical cancer 
patients during the entire treatment course. Image is taken from (32) 
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This thesis 
The primary aim of this study is to evaluate dosimetric benefits between IMRT and IMPT for 
locally advanced cervical cancer. The secondary aim is to investigate the effects of a reduced 
margin and its dosimetric impact on IMRT and IMPT.  
More explicitly, the following research questions are addressed in this thesis: 
1. Does IMPT reduce dose to normal organs at risk for cervical cancer patients 
comparative to IMRT using clinical margins? 
2. How does a reduced margin influence this result? 
3. Does smaller margin benefits in sparing normal organs at risk for IMRT as compare to 
clinical margins?  
 
 
 
 
16 
 
2 Background 
2.1 Cancer 
Human body is made up of many types of cells. These cells grow and divide in a controlled 
way to replace the old and damaged cells after they die to keep the body healthy. When 
genetic material of the cells “DNA” undergoes change, this can cause mutation. Such 
mutation can leads to abnormal and uncontrolled multiplication of the affected cells results in 
the mass of the tissue known as tumour. Cancer is the class of diseases characterized by 
uncontrolled growth and division of abnormal cells. 
There are over 100 different types of cancers (33) and each is named after the type of cell it is 
initially originated from. Cancer types are grouped in two broader categories: Malignant and 
benign tumours. Malignant tumours are invasive and can manage to move to the other part of 
the body through blood vessels and lymphatic system. This activity is termed as “distant 
metastasis”. Moreover, these cells manage to grow and divide, forming new blood vessels to 
feed itself in the process called “angiogenesis”. Hence, malignant tumours are more 
dangerous and difficult to treat as they exhibit distant metastasis. Unlike malignant tumours, 
benign tumours are not invasive. They stay at one spot and demonstrate limited growth and 
consequently, less harmful and can easily be removed depending upon site (e.g. Brain). 
Carcinogens are substances directly responsible for the DNA damage and promoting cancer. 
These substances can be tobacco, arsenics, ionizing radiation like x-rays and gamma rays, etc.  
They interact with our body and form free radicals which in turn try to steal the electrons 
from the DNA molecule of the normal cells causing damage to the cells and hence affect their 
ability to function normally (34). 
The extent and localization of the spread of the disease can be assessed by utilizing medical 
imaging techniques. Doctors may also do endoscopy to look inside the body for the 
abnormalities. However, concerning the characterization of the disease, biopsy is the gold 
standard to verify the presence of cancer. The possible ways to cure cancer are chemotherapy, 
radiation therapy and undergoing surgical procedure. The choice of the treatment procedure is 
done in view of the type and position of the tumour, over and above, the age of the patient and 
the grade of the disease (33, 34). 
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2.2  Cervical cancer 
Cervical Cancer is the second most common cancer in women worldwide, with an estimated 
530000 new cases every year. Out of the total number of cases, more than 270000 women die 
every year from cervical cancer (World Health Organization, 2013). In Norway, the number 
of new cases reported in 2013 was 282 (35). 
Cervical cancer is the abnormal growth in the epithelial lining of the cervix. The greatest risk 
factor behind the development of more than 99% of the cervical cancer is Human 
Papillomavirus (HPV), followed by smoking and weak immune system. There are more than 
100 types of HPV. Most of the HPV types are low-risk types and do not cause cancer. 
However, high-risk HPV types may cause cervical cell abnormalities. About 70% of the 
cervical cancer can be attributed to HPV type 16 and 18 which are considered as High-risk 
HPV types. HPV infection can be caused by the sexual intercourse or by having multiple 
partners, however not all the HPV infected women develop cancer. Most of the HPV 
infections are eliminated by the host’s immune system without intervention. On the contrary, 
some women have persistent infection. These viruses have high risk of transforming normal 
cells into abnormal, which may further then develop to cervical carcinoma (36). 
According to FIGO (International Federation of Gynecology and Obstetrics), cervical cancer 
is classified into various stages depending upon the extent of invasiveness in other part of the 
body (table 1). Staging is based on clinical examination rather than surgical procedures or 
imaging (37). 
                                                                                                                                             
Figure 3-10 shown below illustrates the various stages of cervical cancer extending from 
stage I to stage IV (38). Stage I cervical cancer is usually treated with surgery. But, in case of 
IB2 and IIA stage, combined chemotherapy and radiation therapy may be used. Stage IIB and 
III (A and B) are usually treated with combined chemotherapy and radiation therapy. In Stage 
IV, surgery, chemotherapy, radiation therapy or a combination of these treatments are usually 
chosen to control the symptoms of the disease. 
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                      Figure 3: Stage IA1 and IA2                                 Figure 4: Stage IB1 and IB2 
 
 
 
        
                                 Figure 5: Stage IIA                                                                      Figure 6: Stage IIB 
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                                 Figure 7: Stage IIIA                                                     Figure 8: Stage IIIB 
 
 
 
     Figure 9: Stage IVA                                                          Figure 10: Stage IVB 
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Table 1 Description of the cervical cancer staging as per FIGO (37). 
Stage Description 
0 Carcinoma in situ, i.e. the carcinoma is situated in the original position. 
 I The carcinoma is strictly confined to the cervix (extension to the uterine corpus should be 
disregarded). 
IA Invasive cancer is identified only microscopically. (All gross lesions even with superficial 
invasion are stage IIB cancers.) 
IA1 Measured invasion of stroma ≤3mm in depth and ≤7mm width. 
IA2 Measured invasion of stroma >3mm and <5mm in depth and ≤7mm width. 
IB Clinical lesions confined to the cervix, or preclinical lesions greater than stage IA. 
IB1 Clinical lesions no greater than 4 cm in size. 
IB2 Clinical lesions >4 cm in size. 
II The carcinoma extends beyond the uterus, but has not extended onto the pelvic wall or to the 
lower third of vagina. 
IIA Involvement of up to the upper 2/3 of the vagina. No obvious parametrial involvement. 
IIA.1 Clinically visible lesion ≤4cm 
IIA.2 Clinically visible lesion >4cm 
IIB Obvious parametrial involvement but not onto the pelvic sidewall. 
III The carcinoma has extended onto the pelvic sidewall. On rectal examination, there is no 
cancer-free space between the tumour and pelvic sidewall. The tumour involves the lower 
third of the vagina. All cases of hydronephrosis or non-functioning kidney should be included 
unless they are known to be due to other causes. 
IIIA Involvement of the lower vagina but no extension onto pelvic sidewall. 
IIIB Extension onto the pelvic sidewall, or hydronephrosis/non-functioning kidney. 
IV The carcinoma has extended beyond the true pelvis or has clinically involved the mucosa of 
the bladder and/or rectum. 
IVA Spread to adjacent pelvic organs 
IVB Spread to distant organs. 
 
 
2.3 Computed tomography 
Computed tomography provides variety of purposes in various medical disciplines such as 
diagnosis of the cancer and guidance in the intervention procedures (figure 11a). Historically, 
computed tomography has gone through a tremendous and rapid development within the 
context of evolution of the CT. However, the basic principle of the working and construction 
of the CT scanners has remained same throughout the innovation and advancement. 
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Computed tomography uses x-ray beams generated from x-ray tube and an array of detectors 
(figure 11b). The narrow pencil beams of x-rays sweep across the subject in a transverse 
direction and together, the tube-detector assembly is continuously rotated around the subject. 
This translational-rotational motion of the scan allows the measurement of x-ray transmission 
along the subject. Each rotation generates a large series of 2D radiographic projections 
(slices). An image reconstruction algorithm essentially transforms these multiple 2D images 
into the 3D volumetric image of the subject.  
 
  
Figure 11a: Image of Computed Tomography from GE healthcare. 11b: Geometry of fan beam x-rays with an array 
of detectors rotating simultaneously.  
 
Computed tomography imaging is based upon the attenuation characteristics of the different 
structure and tissues in the body. Each slice is divided into a matrix of three dimensional 
volume (tissue) elements known as “Voxels”. Each voxel of the tissue has designated 
attenuation coefficient (µ). X and Y dimension of each voxel lies in the same plane of the 
slice whereas the Z-dimension of the voxel corresponds to the slice thickness. Under the 
image reconstruction process, the attenuation measured along the path of x-ray through the 
voxels is calculated. Therefore, the resultant attenuation along the path of x-ray is the sum of 
attenuation values in each of the voxel. The x-ray attenuation measured at any position of the 
detector can be summarized by the following expression of exponential attenuation law: 
                   I1 = I0 
   
      (1) 
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Where in equation (1), I1 is intensity of the x-rays emitted out from x thickness of tissue and 
I0 is the initial intensity of x-rays without x thickness of tissue. µ is the attenuation coefficient 
of tissue thickness. 
Back to the earlier days of CT, efforts were made to replace the attenuation values with 
another quantity. Hence, the new concept of CT number has been introduced. Thereafter, the 
diagnostic information on the CT image is visualized by the contrast difference. Contrast 
difference is the CT number calculated from attenuation value of each voxel of tissues in the 
reconstruction matrix. The measurement unit for CT number is Hounsfield units (HU). Water 
is used as a reference medium since its attenuation coefficient is zero. The following 
expression is used for the calculation of CT number:  
                         CT number (HU) = [1000 x (µvoxel - µwater)]/ µwater    (2) 
In equation (2), µvoxel is the voxel attenuation coefficient and µwater is attenuation coefficient 
of water.  
Evidently, much smaller contrast differences have been seen for computed tomography 
compared to conventional x-ray radiography. As a result, CT has revealed subtle differences 
between different tissues. The range of the CT number varies between -1000 for air and 
+1000 for bone. Water has CT number of approximately 0 but not exactly 0 due quantum 
noise in image (39, 40)  .   
The possibility of tumour spread locally and distantly is higher in the advanced stages of 
cervical cancer. Therefore, it requires cross-sectional imaging to be performed. The diagnosis 
of the advanced cervical cancer is done with MRI. MRI provides superior soft tissue contrast 
resolution. It has shown significant results in the assessment of the size of the tumour, the 
depth of cervical invasion and distant metastasis. Therefore, cervical cancer is better 
diagnosed on MR imaging (41). Despite all the advantages of the MRI, CT is a preferable 
choice for treatment planning since it provides tissue density information needed for 
calculation of the absorbed dose. Undisputedly, CT plays a primary role in RT treatment 
planning (42). 
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2.4 External beam radiotherapy 
Radiotherapy can be delivered as an external or internal radiotherapy. In external beam 
radiotherapy (EBRT) an external source of radiation is used and directs the radiation at the 
tumour from outside the body. The important steps in radiotherapy are as follows: Imaging 
and tumour localization, target volume and organ delineation, treatment planning, patient 
positioning and treatment verification, and treatment delivery (43). 
2.4.1 Tumour localization and imaging 
Tumour localization in radiotherapy is a whole process from primary, actual tumour 
localization during treatment planning, guiding treatment delivery through patient set-up. 
Patient set-up depends upon the reproducibility of the patient position and immobilization 
devices (44). The success of radiotherapy depends upon ensuring that a tumour and its 
subclinical extension are irradiated efficiently with the tumouricidal dose. For that reason, the 
tumour should be localized properly, delineated precisely and accurately to increase the 
survival rate and minimize the normal tissue damage. The geometric shape, size and location 
of the tumour are defined with clinical examination (inspection, palpation, and endoscopy) 
and optimal imaging methods available for a particular tumour site. However, the radiation 
dose needed to eradicate the tumour is limited by the surrounding normal organs because of 
their organ-dependant radio sensitivity. The normal organ radiation tolerance should always 
be kept in mind while treatment planning otherwise it would cause fatal complications to the 
normal tissues (45). Based on diagnostic imaging, it is radiation oncologist responsibility to 
contour accurately the target volume and the organs at risk to be spared (46). 
The choice of imaging modality depends upon the location of the tumour site and to the 
adjacent sensitive organs. CT and MRI both have become main stage imaging modalities for 
providing high spatial resolution. Both modalities provide superior anatomical geometric data 
of the tumour and anatomical structures to define GTV in 3D radiotherapy treatment planning 
(45). CT imaging is more attractive option for tumour localization. With advances in CT, 4D 
CT imaging provides trajectory information of normal organs while treating moving tumour. 
Serial imaging can also be considered to visualize and quantify the uncertainty due to change 
in tumour size and tissue densities. Thus, serial imaging forms the basis for adaptive 
radiotherapy. Even if the tumour is accurately and precisely contoured, uncertainty does exist 
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due to patient set-up error, organ and target motion due to various physiological processes. 
Therefore, tumour localization plays a crucial role in correcting patient position at treatment 
site. In room cone beam computed tomography imaging (CBCT) can be used for patient 
positioning verification during or before treatment delivery. Hence, tumour localization is 
considered as a range of processes utilized to minimize geometric uncertainties during 
treatment planning and field checking to the treatment itself (47).   
2.4.2 Treatment planning 
Treatment planning is one of the pivotal tasks in radiotherapy. It determines the best 
appropriate way of delivering dose to patient. It deals with several major steps, that includes 
reproducing patient positioning and immobilization at treatment time, accurate delineation of 
target volumes and critical structures, selection of appropriate beam arrangement and 
configuration, computation of dose to be delivered, evaluation of resulting dose distribution 
and transfer of information from treatment planning system to treatment delivery system (47). 
X-ray CT images forms the basis for treatment planning, but, in case of soft tissue contouring 
MR images can also be acquired as an adjuvant to CT for accurate judgment of target and 
normal tissue delineation. Dose computation algorithms perform complex calculation of dose 
to be delivered. Therefore, model based algorithms has become an integral feature of 
radiotherapy treatment planning systems. Utilizing the fact that each voxel represents a CT 
number and one to one relation between CT number and electron density, voxels in the CT 
image set forms the most applicable representation of patient for dose calculation algorithms 
(47).  
Introduction of 3D treatment planning has given more degree of freedom to radiation therapy 
treatment planning. Consequently, faster and precise evaluation tools are essentially required 
to simply this process. Isodose curves are one of those essential treatment evaluation tools. 
Isodose information is displayed on 3D treatment plan. Isodose curves can be defined as a 
surface or line of equal doses overlaid on a patient’s planning image. Isodose curves can be 
displayed in both absolute and relative dose. The corresponding isodose curves can also be 
seen in color wash display, which may be easier to understand than the standard isodose 
curves (48). An illustration of 3D dose display is visualized in figure 12, where different color 
in the image indicates a particular dose level in relative dose (where the dose is expressed as a 
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percentage of reference doses). However, the 3D dose distribution shown below corresponds 
to IMRT and hence, it will be discussed later in detail in section 2.4.4 
 
 
Figure 12: 3D isodose display in color wash mode for corresponding isodose curves in IMRT treatment plan. Red, 
yellow, pink, sky blue, blue, light green indicates 100%, 95%, 90%, 80%, 70% and 60%, respectively. Image source: 
Philips healthcare 
 
 Volumes in treatment planning  
ICRU has attempted to address the issue of geometrical variation in report 50 and 62. ICRU 
has standardized the concepts of prescribing, recording and reporting doses. For that reason, 
ICRU has recommended to define the whole target volume in different sub-volumes. GTV is 
the gross or visible malignant growth. The delineation of resultant GTV is done by outlining 
the area of tumour in each slice and multiplies it by its thickness. GTV has highest tumour 
cell density and hence, an adequate dose must be delivered in order to obtain local tumour 
control. With the progression of treatment time, GTV can change its shape and size due to 
tumour regression, growth or therapeutic intervention. In case of post-operative treatment of 
cervical cancer prior to radiotherapy then no GTVtumour and CTVtumour can be defined due to 
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the changes caused by surgery itself (49). Contrast enhancement, oedema and hyper or hypo 
density of the tissue are the another factors that may result in inaccurate delineation of the 
GTV (50). CTV is the expansion of the GTV with an appropriate margin to cover the 
subclinical extent of the microscopic disease. PTV is the geometrical volume defined during 
treatment planning. It is the volume used in recording and reporting of dose. It encompasses 
CTV with an adequate margin to account for patient set-up uncertainties and organ motion. 
Therefore, it is the patient positioning error and the organ motion which causes the 
geometrical misses in the radiotherapy (47). The concept of PTV was implemented to help in 
the selection of beam sizes and alignments to ensure that an adequate radiation dose must be 
delivered in all parts of CTV. It is considered as 3D envelope in which the GTV and CTV 
reside and move within this volume but not through it. The margins for different types of 
variations and uncertainties to CTV are internal margin (IM) and set-up margin (SM). IM 
accounts for internal physiological movements in organ relative to internal reference point 
whereas SM relates to compensate for error in patient positioning and alignment of 
therapeutic beams (51, 52).  
Treated volume: It is the tissue volume enclosed by an isodose surface that is selected and 
specified by radiation oncologist as being appropriate to achieve tumour eradication. 
Generally, it is the volume enclosed by 95% isodose surface(52). 
Irradiated volume: It is the volume that receives dose considered significant in relation to 
normal tissue tolerance. Usually, this volume is enclosed by 50% isodose level (52). 
Organs at Risk: OARs are the normal anatomical structures located close to the target 
volume or a part of them is in overlap with that target volume. Normal tissues and organs are 
radiosensitive so they significantly influence the process of treatment planning and prescribed 
dose. OARs have significant dose tolerance level which affects the dose-volume constraints in 
optimization. Considering the radiosensitive nature of the OARs, it is desirable to delineate 
the critical structures accurately and dose distribution to these regions is visualized by isodose 
curves or dose-volume histogram (DVH). Moreover, the physiological movement of the 
organs at risk causes geometrical uncertainties; therefore a margin is added to compensate 
errors and uncertainties. 
One of the most significant tasks in the treatment planning is defining the tolerance dose limit 
for organs at risk. Based upon the tolerance dose and radio sensitivity, the critical structures 
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behave differently. Organs at risk are classified in three distinct categories: serial, parallel and 
serial- parallel. Serial organ is a continuous unit and most radiosensitive structure so even if 
the small part of the organ is exposed to dose higher than the acceptable dose limit of the 
organ will cause complete damage of the organ; therefore, even a point dose is significant. 
The spinal cord is the examples of this group. Parallel organ consist of several functional units 
and if one part is damaged, the rest of the organ makes up for the loss. The dose to a given 
volume or mean dose is considered more important for this class of organs. Kidneys are the 
example for the same (50-52). 
 
 Dose-volume analysis 
Dose-Volume Histograms are the mathematical tool of the 3D treatment planning system, 
which summarizes the entire treatment plan into 2D graph. The x-axis and y-axis of the graph 
represents dose and volume receiving dose, respectively. Dose and volume can be expressed 
in both absolute and relative values. DVH doesn’t show any spatial distribution of doses. It is 
an excellent tool to evaluate and compare different optimal isodose distribution of treatment 
plans using dose-volume parameters, isodose curves, colored display of isodose distributions 
in treatment volume, dose homogeneity index and dose conformity index. The required dose-
volume parameters are same between IMRT and IMPT treatment plans. Some useful dose-
volume parameters are shown below in figure 13. 
 
Figure 13: Schematic representation of the dose-volume histogram (DVH). Image source (53) 
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As per Norwegian radiation protection authority report in volume and dose in external 
radiotherapy by Levernes S, definitions of some of the most relevant dose-volume histogram 
parameters are given below: 
D98% - Dose near-minimum, i.e. it is the minimum dose to a specified volume of interest. At least 
98% of the volume is receiving high dose and only 2% volume is receiving low dose. D98% of 
target volume should be equal to or greater than 95% of the prescribed dose. D98% is much 
useful and robust in comparison to D min (D0%). D98% is dose specified to a certain volume, in 
contrast to D min (D0%) which is dose to a point or one voxel. For that reason, D98% is less 
sensitive to any uncertainty in patient movement, dose matrix location (grid size, grid 
placement and steep dose gradient) and resolution. Generally, D98% is estimated for target 
volume to evaluate target coverage.     
D2% - Dose near-maximum, i.e. it is the maximum dose to a specified volume of interest. It implies 
that only 2% of volume receives higher dose. D2% is clinically much useful than D max 
(D100%). The reason is same as explained above for D98%. ICRU recommends the use of D2cc 
instead of D2% in case of larger volumes of organs at risk. Reasonably, D2cc represents a 
constant volume rather than D2% which varies with size of volume of interest. 
D50% - Dose median, i.e. dose received by 50% of the volume. This corresponds to D50% on the 
DVH. D50% indicates equal volumes receives higher and lower dose. This dose parameter is 
suitable for reporting dose in target volume. It is also used to normalize 100% dose in target 
mean. 
D2cc - Clinical maximum dose, i.e. it is the maximum dose in 2cc of the whole body. This 
dose value is suitable to estimate hot spot areas. ICRU recommends that dose to 2cc of the 
volume should not exceed 107% of the prescribed dose. 
V45cc, i.e. it is volume receiving 45Gy. This dose parameter is estimated particularly for bowel 
as per the recommendation from QUANTEC.  
V10Gy, V30Gy and V45Gy, i.e. volume of the organs at risk receiving at least 10, 30 and 45Gy 
respectively. The above defined volume parameters are generally used to estimate the 
volumes of the organs at risk receiving a particular dose level (53). 
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Dose homogeneity index and dose conformity index are the two objective tools to assess the 
quality of the treatment plans. Varieties of formulae are available in literature for dose 
homogeneity index and dose conformity index. The one used in this study are described 
below: 
Dose homogeneity index (DHI): (D2%-D98%)/Dmean. It tells about how homogenous the dose 
distribution is in the target volume. A value of DHI=0 indicates that D2% and D98% is equal 
and hence, high dose homogeneity in target volume (20, 53). 
Dose conformity index (DCI): V95/VPTV. It is the ratio of the PTV receiving 95% of the 
prescribed dose and total PTV volume. A value of DCI=1 indicates high conformity around 
target volume (52). 
2.4.3 Patient positioning and treatment verification 
The primary goal of conformal radiotherapy is to deliver focal radiation dose to a defined 
target volume while limiting concomitant radiation dose to the normal tissues around the 
target. It is important to consider the factors affecting the geometrical accuracy of the 
radiation treatment delivery. The uncertainties in the patient positioning and organ motion are 
the two prime factors responsible for inaccuracies in precision radiotherapy. Therefore, 
rational strategies have to be adopted to overcome the significant geometrical uncertainties 
and achieving maximum tumour control (47). 
In order to understand the various source of error and a way to deal, the errors are further 
categorized in two components: systematic and random error. The systematic component of 
any error is a deviation that occurs in the same direction and, it is of similar magnitude for 
each fraction of radiotherapy. Systematic error occurs particularly at the localization, 
treatment planning and delivery phases. Random component of any error is a deviation that 
varies unpredictably in any direction and, it is of different magnitude for each fraction of 
radiotherapy. Random errors are limited to organ motion, patient movement and inconsistent 
repositioning in daily treatment fraction delivery. Therefore, the uses of immobilization 
device are more likely to affect the random error. It may also be possible to use imaging 
strategies for patient position correction (54). 
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A variety of immobilization devices are available to aid patient positioning. The sole intent of 
utilizing these devices is to limit the patient movement and keep the patient at a fixed and 
well-defined position during localization or treatment. These devices should be rigid and 
comfortable at the same time so that it allows the fast and accurate patient set-up. They should 
ensure the reproducibility of the patient position for each treatment field. This ensures the use 
of minimum CTV-PTV margins in order to reduce random set-up errors. Thus, the amount of 
normal critical tissues and related radiation induced toxicity can be reduced with an adequate 
dose to CTV. Some of the efficient immobilization devices used readily in radiotherapy is 
alpha cradle, vacuum loc bags, knee and arm support (47). 
As quoted in second paragraph, imaging strategies can also be efficiently utilized to minimize 
the random errors in patient positioning. This technique of treatment verification in patient 
positioning to maintain geometrical accuracy is known as “Image-guided radiotherapy”. 
IGRT is a broader term which makes use of imaging to outline target volumes at the time of 
localization and patient positioning for treatment verification. The choice of imaging modality 
depends upon the anatomical site. The images acquired can be kV imaging or MV imaging. 
Some of the well-adopted imaging strategies are online and offline treatment verification, 
also, inter-fractional and intra-fractional treatment verification. In online treatment 
verification, the images are acquired in the treatment room immediately prior to each 
treatment fraction and corrections in patient positioning are made before the treatment 
delivery. The time required in analyzing for set-up accuracy and taking decision either to act 
or not to act should be as low as possible. Beyond a certain time limit, the position of the 
patient may no longer represent true position because of the variation in patient and organ 
motion occurred during that time. In offline treatment verification, the images are acquired in 
the treatment room immediately prior to each treatment fraction but no action for set-up 
correction is taken until the delivery of next treatment fraction. Inter-fraction verification 
indicates the set-up accuracy between different treatment fractions whereas intra-fraction 
verification deals with the set-up accuracy during each treatment fraction. Since intra-fraction 
organ and patient motion are unavoidable during the treatment delivery. Therefore, real-time 
treatment verification strategies are adopted to quantify the geometrical inaccuracy. A 
comparison is made between a reference image and the images acquired during treatment 
delivery. The underline concept is based on the detection of the displacement between the 
acquired images and reference image over an acceptable tolerance level. One such real time 
system uses the co-relation between external skin markers and internal anatomy. If in case the 
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external marker drifts beyond the reference pre-determined tolerance level then the treatment 
can be stopped/gated manually or automatically (54). 
2.4.4 Intensity modulated radiotherapy 
Intensity modulated radiotherapy is an advanced radiotherapy technique used to minimize the 
amount of normal tissue being irradiated in the treatment field. One feasible approach to 
achieve this objective is to use intensity modulated beams across the treatment field whose 
sum will produce relatively uniform high dose within the complex target volume while 
avoiding dose to the neighboring organs at risk. IMRT uses non-uniform radiation beam 
intensities that can be designed using multi leaf collimators (MLCs) which can deliver 
spatially modulated dose distribution in each radiation beam. Typically, the combination of 
the multiple intensity modulated radiation fields from different directions will produce custom 
tailored radiation dose to the tumour volume and minimizing dose to the normal critical 
structures (55). The effective use of the inverse planning optimization algorithm enables the 
RT planner to find the best beam parameters (beam weights) based upon delineation, desired 
dose objectives and weighting factors associated with target volume and critical structures to 
calculate an optimum planned dose distribution. Thus, IMRT requires the precise 
identification of the exact location and shape of the tumour volume.  
Technically, the geometrical arrangement of the target region and the surrounding normal 
tissues demands the precise selection of the beam angles and beam directions at which the 
radiation is delivered to the tumour. Each radiation beam is delivered to the target in multiple 
segments or subfields varying in shape, size and intensity. The number of segments required 
increases with the complexity of the geometrical arrangement of a clinical case to achieve an 
optimal dose plan. Multiple fixed gantry angles ensure less integral dose compared to 
rotational deliveries such as VMAT and tomotherapy (47). 
 
 Linear accelerators 
For the treatment of cervical cancer, several high energy photon beams are applied to deliver 
high dose to centrally located primary tumour without giving too high dose to normal critical 
structures in the pelvic region. The most widely used sources of external beam radiotherapy 
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are high energy photons which are generated using linear accelerators, known as linac (figure 
14a). Commercially available medical accelerators produce high energy photons. They have 
the energy typically in the range of 4-15Mev. The principle of a linac is as follows: electrons 
are produced from electron gun filament and accelerated to high velocity by applying high 
electric potential across the waveguide. The electron beam is guided throughout the 
waveguide using beam focusing and beam steering magnets. After taking exit from secondary 
part of the waveguide, these accelerated electron beam bends by the application of three 
bending magnets so as to direct the electron beam to hit the target. Then photons are produced 
in rapid deceleration of the electron beam undergoing columbic interaction in the target 
material (generally tungsten). This phenomenon of x-ray production is known as 
“Bremsstrahlung radiation” (figure 14b). The x-ray spectrum produced will be polyenergetic 
where the maximum energy in the spectrum will be defined by the maximum electric 
potential applied. The average x-ray energy is generally 1/3 of the maximum energy. The 
shape and the intensity of the x-ray spectrum are modified by multi-leaf collimators, wedges 
and field blocks. 
 
 
Figure 14a: Representation of linear accelerator. Image on the left shows the clinical linear accelerator with its 
components. Figure 14b: Image on the right illustrates the production and delivery of photon beams with their 
corresponding components in the head assembly. Image 14a source: varian.com 
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 Intensity modulation and beam shaping devices 
The intensity of the beam generated by linear accelerator is modulated by multi leaf 
collimators (MLCs). Multi leaf collimators are located in the head assembly of the linear 
accelerator. MLCs are used to modify and collimate the x-ray beam intensity. MLCs are 
dynamically controlled leaves move in the opposing pair and flexibly shape the treatment 
field into any irregular shape to conform the dose to the tumour and hence blocking dose to 
the adjacent normal tissues. Figure 15a: shows the multi-leaf collimator assembly. They are 
leaves of tungsten usually having thickness range of 0.5 to 1cm (width defined at isocentre 
distance). MLC thickness and design varies with different vendors. Figure 15b: visualize the 
concept of irregular beam shaping using multi-leaf collimator assembly. Collimator assembly 
is integrated with digitally controlled leaves that move with rapid leaf speed for effective 
modulation. MLCs are combined with the collimator jaws in the collimator assembly. Each 
MLC design has its own characteristic resulting in lead transmission, interleaf leakage and 
end leaf leakage (56). 
Similar intensity modulation could be created by physical modulators compensators but it is 
an unpractical alternative as construction and placement of compensators for each radiation 
beam is time consuming and tedious. Therefore, it is efficient to employ automated controlled 
dynamic driven leaf collimators in irregularly shaping the radiation field from the beam eye 
view perspective. Therefore, MLCs perform an important role in conformal therapy (56).
  
 IMRT leaf delivery sequence 
The shape of intensity modulated profile delivered by any leaf sequence is determined by the 
position of the leaf end set at each control point of the sequence. There are multiple sequences 
possible to deliver a desired intensity modulated beam. The series of leaf sequences are 
formed with associated beam weight for each leaf positions. Multiple static fields are 
subdivided into small segments. In each static treatment field, leaves take step to from 
segment while the radiation is off and start irradiation after the leaves are properly positioned. 
This type of dose delivery is commonly known as step and shoot (or segmental MLC). When 
leaves at one side move to the other side at variable speed while the radiation is constantly 
delivered at constant dose rate. This type of dose delivery is known as sliding window 
(dynamic MLC) technique (56). 
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Figure 15a: Multi-leaf collimator assembly and 15b: shaping of the leaves to produce conformity of the radiation field 
to tumour shape. Image source: varian.com 
 
 Dose planning 
Dose planning for photon beam takes into consideration its physical and dosimetric 
characteristics. It is important to understand the depth dose deposition pattern of photon 
beams to shape the dose around target volume. Photon deposit maximum energy close to the 
skin surface after build up region and thereafter, the energy deposition decreases 
exponentially with depth in tissue. Skin surface dose increases with the increase in beam 
energy due to larger build up region. A typical percentage depth dose distribution of photon 
beam at central axis of its path length in patient has been shown in figure 16 (57). 
 
Figure 16: A typical depth dose distribution of photon beam at central axis of its pathlength. Ds is the skin surface 
dose at Z=0, Dmax is the maximum dose often normalized to 100% dose at a depth of Zmax and Dex is the exit dose at a 
depth distance of Zex. The distance between Z=0(Ds) and Zmax (Dmax) is known as build up region. Image source (57) 
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The complex shape of tumor demands precise dose delivery to target volume. Therefore, 
multiple intensity modulated fields from different projections are required to shape 
concavities around tumor and minimizing the volume of normal tissue from irradiation. 
Illustration of multiple intensity modulated beams is shown in figure 12. Therefore, choices of 
beam properties (beam weight) are made through inverse planning optimization during 
treatment planning process (57). 
 Inverse planning 
IMRT treatment planning involves inverse planning where the target volume and critical 
structures are clearly defined and dose objectives to obtain optimum planned dose distribution 
are specified (56). Dose conformity to the target volume is often a clinical requirement but it 
is difficult to accomplish in clinic due to the presence of critical structures in the vicinity of 
target volume. Furthermore, if the critical structures are located in the concavity of the tumour 
volume then it is hard to keep the dose off this region. This may incur unavoidable 
complications and indisputably limiting the dose to be delivered. The above addressed issues 
limits successful radiotherapy. However, the employment of multiple intensity-modulated 
beams (IMBs) have shown its potential in shaping dose around the target volume precisely 
and quite satisfactorily fulfilled the clinical requirements of conformal radiotherapy. Figure 
17 shows the advantage of the IMBs to shape the beam profile of the individual field shape 
and consequently, the collaboration of the multiple beams delivers high dose conformity to 
the concave target shape. Generally, the more complex the geometrical arrangement, the 
larger the number of fields segment required to achieve the optimal plan (47). 
 
Figure 17: Demonstrates the potential of Intensity modulated radiation therapy in shaping the beam profile of the 
individual fields to conform high dose to concave region of the target shape. Image source (56) 
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Inverse planning is called inverse in the sense that the dose is specified to the point in the 
target volume and a mathematical algorithm works backward to compute the optimal dose 
distribution and the corresponding beam weights that match the prescription as close as 
possible (58). The general goal of the inverse treatment planning is to obtain low dose to the 
volume outside target and high dose inside. Success of the optimization algorithm depends 
upon how accurately and closely the solution satisfies the specified dose volume objectives. 
Since the process is iterative and interactive the RT planner slides the volume value to the 
lowest achievable while not compromising the target coverage. The problem arises if the 
given dose volume constraints are vague, that causes non-optimal results and often no 
solution. 
 
 Optimization algorithm 
The mathematical optimization algorithm uses physical (dose, volume) parameters to find out 
best possible treatment plan. Ideally, dose is calculated from each voxel on the 3D image. The 
dose calculation is based on beamlets associated with each treatment beam. Each beamlet is 
subdivided into small intensity elements called “bixel”. The 2D elements on the dose matrix 
represent bixel weights. The beam intensity map is directly proportional to matrix of bixel 
weights. The dose calculation estimates the dose delivered by each beam equivalent to the 
values stored in each beam’s bixel matrix. Once the dose is calculated for each beam, the 
voxels on the 3D image contain the calculated dose values. The fundamental role of the 
optimization algorithm is to select those bixel weights that deliver the most favorable dose 
distribution. The parameter used to do assessment is the cost function or the objective 
function (47). Figure 18 is an example of the beam intensity map. 
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Figure 18: Exemplifies the beam intensity map. Each square represents a bixel. The rows and column are labelled 
with an index l and m respectively. Each square represents a bixel with a beam weight of     . Bixels blocked by 
MLC leaves are displayed white and shades of gray indicates beam intensity levels. Black corresponds to highest 
intensity level. Image source: (47) 
 
The cost function is a measure of fit between a calculated dose distribution and some ideal, 
user specified dose distribution. The optimization of the bixel weights employ numerical 
method to find a set of beam-weights that corresponds to minimum of cost function. Fast 
simulated annealing is one of the numerical iterative methods to find the cost function 
minimum. In each iteration, grains of the beam weights randomly selected from Cauchy 
distribution perturbs the set of beam weights causes the individual beam weights to either 
increase or decrease. The resulting cost function is compared with the running cost function 
value (lowest cost function value from previous iteration). If the new cost function value is 
lower than the running value, then the running value is set to new value and the new beam 
weights are stored in the dose matrix. The process keeps on repeating until the best set of 
beam weights are found corresponding to the minimum of the cost function (58). 
The minimum of the cost function defines the close of the computed dose distribution to the 
prescribed dose distribution. The overall cost function (      ) has been subdivided into 
component terms:                . The dose is calculated in each of the clinical region. 
Following are the mathematical representation of the clinical dose in each region. 
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  : Dose to the ith volume element, the number 100 represents the desire 100% uniform dose 
to the PTV. Wptv, Woar and Wbody are the weighting factor used to stress the relative 
importance of the PTV, OARs and Body respectively. n is the iteration number, subscript ST 
denotes the starting value of the term (i.e. at n=1), m is the number of OARs. 
In nutshell, minimizing the overall cost function        is based upon attaining a uniform 
homogenous dose in the planning target volume (PTV) and minimizing integral dose to the 
OARs and body (58). 
2.4.5 Proton therapy 
Proton, being a charge particle shows different dosimetric characteristics than photons. 
Photon, after a small build up looses energy exponentially with tissue penetration depth 
thereby low dose to the target volume and high dose proximally (figure 16). In contrast, 
protons loose energy in interaction with orbital electrons or nuclear interactions as they 
traverse through the tissue. Decrease in their velocity causes increase in interaction time 
which in turn results in maximum energy deposition near the end of range of proton beam 
known as ‘Bragg peak’. The individual pristine Bragg peaks of successively lower energies 
and intensities are superimposed to yield a spread out Bragg peak (SOBP). The individual 
proton beams from different directions are positioned in target area and combined together to 
yield a distinct localized high-dose concentration. This creates a highly conformal dose 
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distribution with accurately covering the tumour volume while sparing healthy tissues in 
comparison to the photon therapy (59). Figure 19a illustrates the dose distribution curve of 
protons and the concept of spread out Bragg peak (SOBP). Figure 19b shows the difference in 
dose distribution by photons and protons. 
 
 
Figure 19a): on the left illustrates a clinical spread out Bragg peak as a superimposition of the multiple individual 
pristine Bragg peaks of different energy and intensity. 19b): Comparison of the depth dose deposition pattern of 
SOBP protons and 15MV photons with respect to tumour volume. Image source: (60) 
 
The rationale for the clinical use of the proton beams is the feasibility of delivering higher 
doses to the tumour, leading to an increased tumour control probability (TCP). It can also be 
used to lower the dose to OARs and hence, potentially lowering normal tissue complication 
probability (NTCP) (61). Due to its potential in steep dose gradient comparative to the 
photons, results in highly conformal high-dose region while substantially sparing irradiation 
in the volume of normal tissues. Therefore, proton therapy is well suited for irregular lesions 
near sensitive structures. Protons deliver less integral dose to the critical structures by the 
factor of two compared to the intensity modulated photon plans (62). 
 
 Proton beam production 
Proton originates from ion source where hydrogen atom is separated in electron and proton. 
Protons are injected into cyclotron or synchrotron where they are accelerated. Figure 20 
depicts the pictorial description of the principle in cyclotron. Cyclotron consists of dipole 
magnets placed parallel to each other with a gap in between. The dipole magnets produce 
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uniform magnetic field and electric field is produced across the gap by an oscillating voltage. 
The protons are injected in the magnetic field and follow semicircular path until they reach 
the gap where they are accelerated for another half of a semi-circular path. In the meantime, 
polarities of the dipole magnets are reversed thereby accelerating the protons with high speed. 
The size of the magnets and the strength of the magnetic field decide the maximum energy 
produced by a cyclotron. The maximum proton beam energy is directly proportional to the 
maximum range in the tissue. For example, proton beam energy of 230Mev is equivalent to 
32cm range in tissue (59). 
 
Figure 20:Pictorial description of the beam, electric and magnetic fields in a cyclotron. Electric field accelerates the 
protons every time they cross the gap. Magnetic field limits the beam in the Dee volume until the beam reaches to 
maximum energy and extracted from the edge of cyclotron. Image source: (60) 
 
Cyclotrons can be either isochronous or synchrocyclotron. In isochronous cyclotron, all the 
protons have same orbital period regardless of the radius and speed of particles. As a result, 
RF power operates at a single frequency and hence, a continuous wave is produced. 
Isochronous are well suited for beam scanning technique (it will be described later) because 
beam can be turned on and off quickly with short response time during beam current 
modification. Since the isochronous cyclotron extracts the fixed proton beam energy, an 
energy selection system needs to be placed in the beam line. It consists of carbon wedge 
degrader of variable thickness to move in and out of the proton beam. As a result, increases 
emittance, energy spread and reduces efficiency. Moreover, the use of degradation material in 
beam path leads to secondary radiation and, hence, more shielding is required. In 
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synchrocyclotron, the driving RF electric field is not kept constant so as to compensate for the 
increasing velocity of particles (59). 
Synchrotron, it is a circular accelerator ring enclosed in electromagnetic resonating cavities 
which accelerates the particles. As the particle energy increases with each turn, the magnetic 
field strength needs to be changed to synchronize the particle energy with magnetic field 
strength. This approach allows the ability of the synchrotron to produce pulsed beam of 
variable energies (59). 
The major advantage of synchrotron is its ability to produce proton beam of variable energies. 
Consequently, no use of energy degrader system that will avoid secondary radiation. Overall, 
synchrotron is a more flexible solution over cyclotron in the generation of proton beams (59). 
 
 Beam delivery techniques 
Passive beam scattering:  
Passive beam scattering uses arrangements of scatterers and degraders to spread out the beam 
to cover the treatment field and extend in depth of the PTV. The spreading of the beam occurs 
in the section of the beam line called “nozzle”, to achieve adequate conformation of the dose 
to the PTV (60). A single scatterer lead slab (High Z material) broadens the beam sufficiently 
for the coverage of the small fields. For larger fields, a second scatterer is needed to ensure a 
uniform, flat lateral dose profile (63, 64). In case of deep seated targets, range modulators in 
addition to scatterers are used to spread out the Bragg peak in depth. Range modulator is 
basically a propeller based object of successive layers of varying thickness. Each layer pulls 
back the Bragg peak of the each pristine proton beam proportional to the water equivalent 
thickness of the layer to form the flat characteristic spread out Bragg peak (SOBP). In case 
the distal part of the target is shallower than the range of the beam, constant thickness range 
shifter can be employed to achieve a global adjustment of the SOBP depth to match the depth 
of target volume. This setup is placed upstream near the nozzle entrance and contributes for 
upstream modulation, whereas traditionally the range modulators were used close to the 
patient called downstream modulation, so that the scattering in the modulator itself can be 
ignored but it causes the edges of the dose distribution less sharp (60). 
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Alternatively, range modulation is accomplished by inserting the individual constant 
thickness degraders and scatterers into the beam in a programmed way. The plastic degrader 
and lead scatterer combination is most often used since low Z-material (Plastic) and high Z 
material (lead) can stop the protons more efficiently with correspondingly minimum 
scattering at each depth. The SOBP is created step-wise in a process called lamination. 
Because of the switch over time between degraders, lamination delivers the proton beam 
sequentially as a function of range and this increases sensitivity to organ motion in the depth 
dimension, not in lateral dimension as it is produced by scattering over the entire treatment 
field. The number of modulator required to cover all clinical requirements can be efficiently 
reduced by varying the beam current during the modulation cycle. Beam current modulation 
from zero to full beam current provides the full dynamic control of the creation of the SOBP 
depth dose profile independent of the particular range modulator (60). Figure 21 demonstrate 
the double scattering nozzle with sequentially placed beam modifying components. 
 
 
Figure 21: Illustrates double-scattering nozzle with relevant beam modifying components. FS= First scatterer of lead 
foil, RM=range modulator, SS=second scatterer, RS=range shifter, Jaws, IC=ionization chamber, Snout, AP= 
aperture, RC= range compensator. Image source: (60) 
 
Double scattering uses second scatterer to reduce energy loss and produce uniform, lateral 
dose profile thus making the large fields practical. It can be seen in figure 22. The upstream 
range modulator S1 serves both as range sifter and primary scatterer to produce a non-uniform 
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Gaussian on the secondary scatterer S2, modified to produce a flat or nearly flat dose 
distribution at the patient. The second scatterer typically consists of the two materials, that is 
high Z material to maximize the scattering and minimize the range loss whereas a low Z 
material to minimize the scattering and maximize the range loss. In order to flatten the beam 
profile the protons at the field centre must be scattered more than the protons further outside 
the field centre thus resulting in the optimized profile of useful radius R (60). 
 
 
Figure 22: Double scattering with upstream range modulator. Image source: (60) 
 
The major disadvantage of the dual scattering is an increased sensitivity to beam steering. The 
mechanical or beam steering magnet error can easily cause the beam to tilt off centre as little 
as millimeter on the secondary scatterer which correspondingly tilt the flat dose distribution at 
the patient (60).  
Aperture: It is a patient specific hardware device made up of brass with a hole inside to fit 
the outer projection of the target beam’s eye view. It is used for the lateral dose conformation 
to the target and in addition eliminates the proton heading outside the PTV (60). 
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Range compensator: It is complex shaped plastic block which is used to tailor the dose in 
depth by shifting the proton range depending upon the PTV shape to achieve the distal dose 
conformation (60).  
Lateral and Distal dose fall off:  
Practically, it is important to have a good nozzle design. Primary and secondary scatterer or 
range modulators should be placed far upstream from the patient to produce the sharp dose 
distribution. Further, scattering occurs in the patient resulting in unavoidable poor dose 
gradient for the deep seated tumour, no matter how good the nozzle design is.  
Moreover, air gap is another significant factor deciding the dose gradient for the target 
volume. For illustration, large air gap between the final aperture and patient spoils the lateral 
dose fall off. Unlike lateral dose fall off, the distal dose fall off is determined by the shape of 
the Bragg peak. Both aperture and compensator are mounted on the retractable snout on the 
treatment head. The retractable snout ensures that the air gap between the beam shaping 
devices and patient should be kept as low as possible to reduce the effects of scattering in air, 
which causes softening of the beam penumbra (60). 
 
Beam scanning techniques:  
One peculiar characteristic of the protons is its charge which enables magnetic deflection of a 
narrow pencil beams. Proton beam can be scanned in the lateral direction (x-y) through 
magnetic deflection across the target volume and modulation in depth (z) can be achieved by 
dynamically varying energy of the protons (60). 
In principle, the individual narrow pencil beam is scanned across the target volume layer by 
layer at various depths. One can initiate with the deepest layer with highest energy and scan in 
zigzag fashion. With the change in energy, the next layer is repainted and so forth until the 
whole target volume has been scanned. For each layer intensity needs to be modulated as the 
distal part of SOBP delivers more doses depending upon the shape of the distal surface than to 
the proximal layer in order to generate the uniform target dose and conformity. Each layer 
may be repainted multiple times in order to avoid delivery error and uncertainties (60). 
Individual pencil beams are sequentially deposited onto the patient under computer control 
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and range of the beams can be adjusted as a function of beam position in both X-Y and Z 
direction called variable range modulation (65). 
Spot scanning proton therapy (SSPT) is the fast, dynamic scanning of a proton pencil beam 
over a target volume to provide better conformal coverage. SSPT can be delivered, either by 
using multifield optimization (MFO) or single field optimization (SFO). In MFO, all spots 
from all fields are optimized simultaneously. In SFO, each field is optimized individually to 
deliver the prescribed dose to the target volume while respecting tolerance of the normal 
structures. SFO, is also known as single-field uniform dose (SFUD). MFO has so far only 
been introduced in combination with IMPT. It is important to note that in IMPT, it is the 
modulation of particle number rather than beam intensity(66). In MFO-IMPT, non-uniform 
dose distributions are delivered from each treatment field at a given direction, with large dose 
gradients. The desired uniform dose in the target volume is achieved by summing the dose 
contributions from all the fields. MFO-IMPT is sensitive to range and set-up uncertainties. On 
the other hand, SFO has more robustness but constant and limited modulation unable it to 
achieve OARs sparing (59, 67).  
Intensity Modulation proton therapy (IMPT) can only be done by pencil beam scanning. 
IMPT is analogy to intensity modulated radiation therapy. Various modes of the beam 
scanning techniques have been devised as follows: 
Discrete Spot scanning: It is a specific mode of beam scanning where a beam is moved to 
the static position without delivering the dose and the dose is delivered once the correct 
position has been achieved. It is similar to step & shoot approach of the IMRT, it keeps the 
constant magnetic settings when targeting at the static spot (68). Then the beam is switched 
off and the magnet settings are changed to target the next spot and so forth. Of note is the fact 
that intensity modulation is produced by causing the variation in the irradiation time per spot, 
not the variation in beam intensity. The scanning is done in longitudinal dimension only and 
the other dimensions are being achieved by couch movement.  
Dynamic spot scanning: Here the beam scanning is done continuously across the target 
volume. The intensity modulation is achieved through the modulation of the beam current or 
by modulating speed of the scan, or both. It has several advantages over discrete spot 
scanning as it results in faster delivery and shorter beam-on time. Therefore, it is less sensitive 
to organ motion and more efficient in avoiding range uncertainties.   
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Wobbling: It is the application of relatively broad beam (diameter in the order of 5cm) 
scanning across the target volume. It results in broad penumbra. The easy achievement of 
larger field sizes than attained from passive scattering accounts for its advantage. 
One advantage of the MFO-IMPT is that the modulation width of the SOBP in each pencil 
beam axis can be varied along the length of the target. Therefore, region of 100% dose in the 
Bragg peak is strictly confined within the target and reduces skin dose. It delivers 3D 
conformal dose distribution in lateral, proximal and distal dimensions. In contrast, the beam 
scattering employs constant modulation width and is equal to the maximum length of the 
target along each broad beam axis resulting in some unnecessary amount of dose spilling 
proximal to the target volume, especially at places where the target shrinks. Another 
advantage of the MFO-IMPT technique is the minimum neutron dose deposition due to the 
absence of primary and secondary scatterers as well as the reduction of the field specific 
hardware. Furthermore, the MFO-IMPT approach do not use field or patient specific devices, 
collimators and compensators, therefore sequential fields are delivered without entering into 
the treatment room. Thus, reduces treatment time and increases patient throughput. The 
biggest advantage of the MFO-IMPT is the utilization of full flexibility and variability of the 
spot scanning technique and hence, it is potentially capable in increasing OARs sparing (60). 
Accounting for its disadvantages, MFO-IMPT approach has higher sensitivity to organ 
motion comparative to passive scattering (69, 70). Another disadvantage is the technical 
complication to generate very narrow pencil beams (59). 
IMPT has dosimetric advantages over IMRT: It is possible to construct steeper dose gradient 
with scanned proton beams. For that obvious reason it is feasible to shape 3D conformal dose 
distributions with convexities and holes and can avoid those pencil beams which point at 
sensitive structure or pass through complex density heterogeneities (60). 
 
 Target volumes in proton therapy 
The concept of target volumes is similar to both photons and protons except little dissimilarity 
in PTV owes to range uncertainties for protons. Particularly for protons, the concept of PTV 
margin depends primarily upon their physical properties as opposed to geometrical properties 
of the field for photons, where physical properties signify range uncertainty due to distal dose 
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fall-off and geometrical properties indicate beam position, respectively (71). The PTV is used 
primarily to determine lateral beam margins as well as distal margins (margins in depth) to 
account for range uncertainties. Correspondingly, for photons PTV is just used to determine 
the lateral beam margins. Protons in principle need a separate PTV with different lateral and 
distal margins for each beam orientation. It is therefore unpractical to use different PTV for 
each beam employed and incorporating computer beam-design algorithm for separate lateral 
and distal margins. As a result, for protons the PTV will be defined relative to the CTV for 
lateral uncertainties alone and adjustment will be made in the computer beam algorithm in 
case of differences between margins needed to account for uncertainties along the beam 
direction (i.e. range uncertainties) and PTV (i.e. based on lateral uncertainties) (72).   
 
 Patient positioning and immobilization 
Generally, most part of the patient positioning and immobilization in IMRT applies equally 
well to the proton therapy. Unlike in IMRT, online patient position verification and correction 
protocol extends to not only verify after initial patient set-up but also before each field within 
the treatment fraction. Moreover, the use of latest image information for intra-fractional 
verification guarantees the best tumour coverage and the efficient sparing of the normal 
tissues. However, there are few issues significantly specific to proton therapy. One of the 
major differences relates to the physical properties of the protons. Since, proton has no build 
up effect on skin so this allows the use of immobilization device in contact with the skin. 
Other relates to the range of the proton particles. Proton ranges are adversely affected by the 
sharp dose fall off at distal end due to the variation in radiological depth of the SOBP. 
Furthermore, immobilization devices do have influence on lateral dose gradient. Lateral dose 
penumbra can be influenced by both increase in distance from beam source to patient, and an 
increase in aperture to patient distance. Therefore, the radiological and geometrical thickness 
of the immobilization devices should be kept to minimum to have maximum dose conformity 
around target area and minimum risk to organs at risk laterally to beam direction. Treatment 
couch also causes increase in distance between beam limiting device and the target; thereby 
increase in lateral dose fall. All these factors affecting distal and lateral dose conformation 
should be taken into consideration during treatment planning. Whereas, in case of scanning 
beams the knowledge of tumour motion and immobilization is even more important because 
of interference effects between scanned proton beam and moving tumour. Therefore, it is 
48 
 
important to ensure the correct position of the tumour and critical structures as planned to 
avoid the geometrical misalignments (71). 
 
 Inverse planning 
An appropriate inverse treatment planning system (TPS) is strictly necessary to take full 
benefit of scanning techniques. Inverse planning determines the best fluences of individual 
beams to achieve optimal dose conformation around target volume (73). The resultant 
optimized plan in IMPT is a set of particle fluence distribution, generally known as “fluence 
or intensity map”. Fluence map gives the position of the beam spots with respective 
intensities. Unlike in IMRT, IMPT utilizes different and separate fluence map for each of the 
pencil beam from the same direction in the field. Therefore, for a constant energy setting it is 
possible to deliver fluence maps sequentially from layer to layer (60). 
The only major difference outlining IMPT is that both energy and intensity of the each pencil 
beam should be varied (74). Thus, increases the number of degree of freedom drastically. As a 
result, better dose conformation potential can be achieved with IMPT but the computational 
time and delivery complexity also increases. The dose calculations can be simplified if the 
appropriate intensity modulation technique is pre-selected. One method is distal edge tracking 
(DET) originally explained by Deasy et al, 1997 (75). The Pristine Bragg peaks of the 
individual pencil beams are placed on the distal surface of the target volume with optimized 
intensity modulation thereby creates a highly non-uniform dose per field. Thus, a desired dose 
distribution is obtained by combining all the treatment fields from different directions. DET 
creates steep dose gradient as it shapes the dose distribution with distal fall-off of the Bragg 
peak (distal fall-off of the Bragg peak is sharper than lateral fall-off). For that reason, it is 
difficult to achieve uniform dose in the target volume. DET produces lowest possible integral 
dose because each constituent pencil beam delivers maximum dose at distal edge with 
minimum dose to the critical normal structures. However, this technique is also sensitive to 
range uncertainties. Simpler technique is the 2.5D technique where a spread out Bragg peak 
distribution of the individual pencil beam can be applied to create SOBP modulation. Multiple 
pencil beams of variable modulation width (different energy for each pencil beam) are 
individually shape to the proximal and distal edge of the target volume such that the dose is 
constant along the depth of target volume. The most generally used IMPT technique is 3D-
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modulation; it places the pristine Bragg peaks of the individual pencil beams throughout the 
target volume with optimized intensity modulation (60). Figure 23 shows the different 
approaches for intensity modulation. 
 
 
Figure 23: Three different approaches to intensity modulated proton therapy. The solid circle on the target volume 
represents position of individual Bragg peak. The diameter of the solid circles indicates the relative intensities. Image 
source: (60) 
 
In 3D modulation, treatment fields can be delivered either by layer scanning or by depth 
scanning. Layer scanning can be accomplished by irradiating consecutive layers of equal 
radiological thickness. Constant proton energy should be kept per layer as well as modulation 
of the intensity in the transverse plane. The same process is repeated for next consecutive 
layer and so on with different proton energy settings. Alternatively, depth scanning can also 
be used. For each pencil beam position, a number of depth positions are consecutively 
scanned with highest energy setting for the most distal layer and decreasing the energy for 
successive layers (60). A basic illustration of the dynamic delivery in the IMPT is shown in 
the figure 24 
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Figure 24: The target is sliced in multiple layers. Each layer has a constant radiological depth indicate by energies E1, 
E2 and E3. The target is irradiated in successive layer. Each layer contains a set of pristine Bragg peaks of varying 
intensity to produce desired dose variation within a layer. Image source: (60) 
 
 Optimization algorithm 
Conformity, selectivity and gradient index are the three major entities of the objective 
function. For the purpose of assigning dose-volume objectives to the volume of interest 
(VOI). The 3D patient image is grouped into 3D volume elements called “Voxels”. Volume 
of interest (VOI) consists of voxels as a function of which target volume and critical 
structures are defined. The fluence map provides information about the beam spots with their 
respective intensities. The term optimization in IMPT treatment planning typically signifies 
the search for a set of beam spot weights that minimizes the objective function. The dose-
volume constraints for OARs are specified in such a way that no voxel in the OARs should 
receive that exceeds the maximum tolerance dose limit. Similarly, for target volumes, no 
voxel should receive dose short of prescription dose. Since it is not practically possible to 
satisfy all the constraints simultaneously, hence weighting or penalty factors are also defined 
for the target volumes and OARs. Consequently, the optimized treatment plan represents a 
compromise solution in which the actual and prescribed dose matches as close as possible 
(60). 
The generalized form of the optimized dose function can be expressed as follows: 
Objective function=               
  
       (7) 
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In equation 7, N is the total number of constraints, In is the total number of voxels in a 
volume n and F is the constraint specific objective function (OF) which expresses the 
difference between actual dose distribution (di) and prescription dose (Dn) (60). 
 
2.5 Radiobiology 
Relative biological effectiveness (RBE) is an indicator of the biological effectiveness of the 
radiation dose. As per definition, RBE of protons states that dose of the reference radiation 
(i.e. X-rays) at 250KVp divided by dose of test radiation required to produce the same effect 
(76). Protons are biologically more effective than photons. Basically, it means that protons 
require lower doses to produce the same biological effect as compared to photons. The effect 
ionizing radiation have in a specific biological material is LET dependent, and also influenced 
by factors such as the dose and the individual energy of the irradiating beam particles 
amongst, other. One way to increase the differential radiobiological effect can be modifying 
the radiation quality parameter, i.e. LET. 
Linear energy transfer (LET) has been viewed as a qualitative indicator of the biological 
effects of different kinds of radiation (77). It depends upon nature and initial beam energy of 
the particles. As the charge and energy of the particle changes along particle’s path, LET also 
changes. It is a parameter associated with the change in RBE. The change in the RBE occurs 
with the change in the energy deposition density or LET along the particle’s path. The LET at 
which the maximum RBE occurs is particle specific. The RBE increases continuously along 
the SOBP and significantly at the declining edge of most distal part of the Bragg peak 
resulting in the extension of the biological effectiveness of RBE corrected dose by 1-2 mm 
(78). The maximum LET is 100kev/µm at Bragg peak for protons (77). Beyond that LET 
range, RBE decreases due to over killing effect (dose deposited is more than dose required to 
kill the cells). It is well known that the RBE is not a fixed value, but varies over the physical 
depth dose curve, and also varies with tissue type and with the fraction size. Clinically, a 
generic RBE of 1.1 is applied independent of physical (beam energy, position in SOBP, 
dose/fraction, depth of penetration) and biological (irradiated cell or tissue, biological 
endpoint) parameters as recommended in ICRU report 78 (72). This value is applied to all the 
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tissues types that fall in direct beam path (78). Generic RBE is just a rough approximation and 
it is applied to neglect RBE variations along the SOBP. 
Absorbed dose is a physical quantity in radiation therapy. It is an important predictor of 
clinical outcome but it doesn’t hold a unique correlation to biological effect. Several factors 
like dose/fraction, overall treatment time, dose rate, dose homogeneity as well as radiation 
quality (RBE) influences the clinical outcome. Absorbed dose (D) is defined as the amount of 
energy absorbed per unit mass of the matter irradiated. The dose is expressed in Gy 
(Joule/kg). The same amount of physically deposited dose from different types of radiation 
does not necessarily produce an equal biologic effect in the irradiated tissue. RBE is applied 
to relate proton dose to photon dose. Therefore, to determine what dose of proton is equal in 
producing the same identical biological effect as a certain dose from photons, the RBE 
weighted dose is defined:  
DRBE=D X 1.1, DIsoE = DRBE = D X 1.1, keeping all other irradiation conditions identical 
(dose/fraction, treatment time, etc) .........Where, DRBE is RBE corrected dose in cobalt-gray 
equivalent.            (8) 
In equation 8, the DRBE is the RBE-weighted dose and the D is the physical proton dose in Gy. 
Since, the unit for RBE corrected dose and absorbed dose is same (Gy), therefore, to avoid 
confusion cobalt-gray equivalent (CGE) is used as a unit for RBE corrected dose in protons 
(79). 
The RBE of the SOBP abutting critical normal structures contributes dose at the distal end are 
of principal concern. This clinical consequence compel the treatment planners in not utilizing 
one of the dosimetric advantage of the protons, namely sharp dose fall-off for single field 
plans (59).  
2.6 Recommended dose-volume constraints for 
limiting OARs toxicity 
2.6.1 Rectum 
The most frequent endpoint used to quantify the dose-volume tolerance for radiation induced 
late effects in rectum is grade≥2, i.e. late rectal toxicity. The volume of rectum receiving dose 
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≥60Gy is constantly associated with risk of grade≥2 or rectal bleeding. Generally, high doses 
are predominantly related to risk of toxicity. Volume receiving dose ≤45Gy are not 
significantly linked to rectal toxicity (80). 
For whole organ volume segmentation, V50Gy<50% (81)  
2.6.2 Bladder 
There exist difficulties in keeping reproducible shape and volume of bladder throughout the 
treatment course due to highly distensible nature, variation in its volume with filling, post 
void residual volume, breathing and positioning. Therefore, partial irradiation of bladder 
doesn’t guarantee the true treated volume of bladder during the course of treatment. Hence, 
reliable dose volume constraints cannot be defined unless the whole pelvic is irradiated.  
Treatment of locally advanced cervix cancer with EBRT alone usually requires higher dose 
(>60Gy) which often results in incidence of late complications (82). Therefore, EBRT is 
combined with brachytherapy. EBRT component of treatment limits the dose to 40-50Gy, and 
rarely outcome severe late effects. However, intra-cavity brachytherapy increases the total 
dose to 70-90Gy, and even higher, to a small volume. Upper dose limit of bladder tolerance 
has yet not been defined. Further study considering the non static nature of bladder and long 
term clinical follow-up is required to produce actual dose-volume tolerance limits for bladder 
(83). 
2.6.3 Bowel 
For whole-organ irradiation, TD5/5 
1
and TD50/5
2
 estimated for small-bowel toxicities were 
40Gy and 55Gy respectively. Whereas for partial organ irradiation (1/3 small-bowel 
irradiation), TD5/5 and TD50/5 estimated were 50Gy and 60Gy. These RT dose limits are 
related to acute and late toxicity risk (84).  
Concurrent chemotherapy in addition to radiotherapy is related to RT-induced acute toxicities 
in small-bowel, and previous abdominal surgery has been linked to higher risk of RT-induced 
late injuries. According to published date in the QUANTEC review for small bowel, 
maximum dose is likely related to late toxicity and volume threshold parameters (VD) are 
                                                 
1
 TD5/5 is the estimated doses with a 5% risk at 5 years 
2
 TD50/5 is the etimated doses with a 50% risk at 5 years 
54 
 
related to acute toxicity. It is important to mention that the results for volume threshold-based 
risks are dependent upon methodology of contouring small bowel. Roeske et al. outlined the 
entire peritoneal cavity (excluding bladder and rectum) as small bowel (11). Such volume is 
associated with dose 45Gy. Therefore, V45Gy should be minimized and kept less than 195cc to 
reduce acute and chronic late toxicities (84). However, according to dose planning in cervix 
cancer at Oslo University Hospital, V45Gy<195cc may be difficult to achieve and 
recommended to use V45Gy<300cc (85). Note that this limit is only valid for pelvic irradiation. 
Treatment plans with para-aortic irradiation in addition to pelvic irradiation are well accepted 
with V45 to 450-600cc. 
2.6.4 Pelvic bone 
The mean dose to pelvic bone is significantly related to the hip and sacral pain for patients 
with pelvic radiotherapy. It was recommended to reduce the Dmean<37.5Gy during treatment 
to lower the chances of long-lasting pain (86).  
2.6.5 Kidneys 
The kidneys are dose-limiting organs in radiotherapy of gynecological cancer when the para-
aortic region is included. Several dose/volume parameters are estimated to evaluate the risk of 
RT-induced renal injury. Risk of kidney injury depends upon the bilateral kidney RT or 
partial volume RT. Kidneys are parallel organ so even if a part of kidney is irradiated, it will 
not cause renal toxicity. For bilateral kidney irradiation, the mean kidney dose (D50%) should 
be <15-18Gy and <28Gy for TD5/5 and TD50/5, respectively. Several other dose volume 
constraints for combined kidneys are given below:  
V12<55% 
V20<32% 
V23<30% 
V28<20% (87)  
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2.6.6 Spinal cord 
With the conventional scheme of 1.8-2Gy per fraction for full cord cross-section, the 
estimated risk of myelopathy is 0.2 at maximum dose (D max) of 50Gy (88) (81). 
2.6.7 Cauda equina 
The maximum dose to cauda equina should not exceed 60Gy, (D max<60Gy) (85).  
2.7 Clinical margins for cervical cancer 
This chapter is taken from a review study done by Jadon et al (22). 
 In the treatment of cervical cancer, the pelvic organs at risk inherently tend to show 
positional and volumetric variation over time. As an effect, any variation in bladder and 
rectum filling can cause change in the cervix-uterus position and shape. Therefore, margins 
are required to ensure CTV coverage and, thus results in unnecessary inclusion of the OARs 
into high dose region. Owning to the steep dose gradients around the PTV produced in the 
conformal therapy, cervix-uterus motion can cause geometrical uncertainties. Thus, cervix-
uterus movement reduces the potential and benefits of conformal radiotherapy in cervical 
cancer. To tackle the issue of cervix-uterus motion, it is important to establish accurate and 
precise strategies. First and foremost step in the implementation of the radiotherapy is the 
accurate delineation of the CTV on the planning CT scan and determining the margins around 
to form PTV. Based upon the knowledge of the extent and pattern of the cervix-uterus motion 
and influences of bladder, rectum filling, CTV-PTV should be kept large enough to minimize 
organ motion and patient set-up uncertainties respectively. R. Jadon et al has reviewed organ 
motion and IGRT strategies in EBRT for cervical cancer. The study had investigated the issue 
of inter-fractional, intra-fractional organ motion and influence of rectal, bladder filling during 
treatment in cervical cancer. It was indicated that the effect of intra-fraction motion is less 
distinct than inter-fraction motion but the internal margin should be selected such that it 
accounts for both. It was confirmed that bladder filling has more impact on uterine motion 
whereas rectum filling is more responsible for cervix motion. They reported displacement of 
up to 15mm in uterus compared to up to 6mm in cervix.  The examination reported a 
maximum of 48mm, 32mm uterine motion relative to 19mm and 12mm cervical motion in A-
P and S-I direction respectively. This validates the fact that uterine is more mobile than 
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cervix. Potential solutions include an isotropic margins of 15.3-21mm and anisotropic 
margins of up to 32mm in A-P, 20mm in S-I and 17.5mm in L-R. This validates that the mean 
CTV-PTV margin of 15mm is not sufficient in encompassing the CTV successfully. 
However, a study by Tyagi et al has investigated that with the use of 15mm CTV-PTV 
margins there exists only a minimal miss of 4cc in CTV, with maximum missing in uterine 
fundus (89). It is important to notify that the presence of microscopic disease in uterine 
fundus is a topic of current research debate and hence, the use of 15mm margins is well 
accepted clinically.   
 Two studies investigated set-up margin using daily CBCT to create PTV for designing 
IMRT/IGRT protocol. These significant set-up margins add up with internal margins to create 
CTV-PTV margins. However, it is recommended to follow institution-specific set-up margins 
as they are determined on specific patient positioning, immobilization, treatment verification 
and imaging protocols. Even though, treatment in prone position has shown the significant 
sparing of the small bowel but it is also coupled with a larger set-up error. The use of 
Generous CTV-PTV margins will diminish the benefit of sparing small bowel. 
Alternative Strategies were considered effective to deal with complex issue of organ motion. 
Strategies include offline and online imaging. However, according to UK national guidance, 
both offline and online imaging are found incompetent in improving treatment accuracy, 
given the unpredictable, complex nature of uterine and patient specific organ motions. 
Therefore, personalized adaptive IGRT strategies are probably the most promising option to 
manage the observed motion. Based upon the analysis of pre-treatment correlation between 
the bladder filling and displacement pattern of the cervix-uterus, a library of treatment plans 
with incremental CTV-PTV margins are created. Using the daily in-room CBCT imaging 
with soft tissue matching, the displacement of the CTV is determined from the planned 
position. Consequently, an appropriate plan of the day is selected from the series of treatment 
plans. 
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3  Study design 
The chapter deals with the methodology utilized to prepare optimum treatment plans. 
Treatment planning was done for IMRT and IMPT based upon dose-volume objectives for 
target volumes and organs at risk. Various evaluation criteria were selected, analyzed and 
compared between both modalities to quantify the dosimetric differences. 
3.1 Patient population 
Ten patients with histologically proven locally advanced cervical cancer were included in this 
comparative treatment planning study. Out of ten patients, five patients received treatment in 
para-aortic region in addition to pelvic irradiation. Staging was done according to 
international federation of gynecologic and obstetrics (FIGO). 
3.2 Imaging for treatment planning 
Computed tomography (CT) imaging was used for treatment planning. Patients were 
instructed to drink 300ml of water after voiding half an hour prior to the CT scanning. The 
same drinking protocol was used prior to each treatment fraction in order to standardize 
bladder volume and, thus, minimize organ motion uncertainties. The CT acquisition was 
performed using slice thickness of 3mm and pixel size of 1mm. The CT scan was performed 
in the supine position using a knee and foot positioning device. The patient’s bladder was kept 
full so as to minimize the organ motion uncertainties.  
3.3 Volume definitions 
Target volumes and organs at risk volumes were delineated on the axial CT images. The GTV 
was defined as GTV tumour and GTV lymph nodes. The central and regional nodal clinical 
target volumes (CTV) were outlined separately. The CTV central included the gross tumour 
volume (GTV) with a 5mm isotropic margin, the cervix, the entire uterus, both parametria and 
3cm margin from the GTV down in the vagina (figure 25). CTV elective was created by 
expanding GTV lymph nodes with 5mm isotropic margin. Pelvic lymph nodes CTV included 
perivascular fat and connective tissue around vessels of the common iliac, external and 
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internal iliac, obturator and presacral lymph nodes. Para-aortic lymph node CTV ranges from 
L4-L5 vertebral body interspace up to the lower border of Th12.  
The GTVs, CTVs and OARs used in this thesis were pre-delineated and hence, they are not a 
part of this study. However, PTV is a geometrical concept so the PTVs were created based 
upon those pre-delineated CTVs during treatment planning. PTV central was created by 
adding margins to the CTV central. Two sets of treatment plans were prepared based on 
different central CTV-PTV margins: anisotropic clinical margin (7 mm L-R, 10 mm S-I, 15 
mm A-P) (figure 25) and isotropic reduced margin (7 mm) (figure 28). PTV elective was 
constituted by CTV elective with 5mm isotropic margin in between (figure 26). The total 
planning target volume (PTV union) was created by combining both PTVs (PTV central and 
PTV elective) (figure 27). 
 
 
 
Figure 25: CTV central (light green)-PTV central (dark red) with 1.5cm anterior-posterior margin and 0.7cm left-
right margin. Image taken from own work. 
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Figure 26: CTV (green)-PTV (cyan) elective with 5mm isotropic margin. Image taken from own work. 
 
 
 
Figure 27: PTV union (blue) = PTV central+ PTV elective with clinical margins (central CTV-PTV margin of 7mm L-
R, 10mm S-I, 15mm A-P). Image taken from own work. 
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Figure 28: Reduction of Central CTV-PTV to 7mm isotropic. Image taken from own work. 
 
The difference in the two PTV union volumes was due to the difference in CTV-PTV central 
margin as indicated in figure 29. 
 
 
Figure 29: The difference between PTV union (blue) based upon clinical margins and PTV union (dark blue) based 
upon reduced margins. PTV union (dark blue) = Reduced 7mm central PTV + PTV elective. Reduction of the PTV 
union (dark blue) volume was due to reduced central CTV-PTV margins (7mm isotropic) from PTV union (blue) 
(clinical central CTV-PTV margins). Image taken from own work. 
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Organs at risk (OARs) included body, bowel, bladder, rectum, sigmoideum, pelvic bone, 
cauda equine, Medulla, left and right kidney. In case OAR is overlapping with PTV, an extra 
helping structure: OAR-PTV was created to reduce the dose in OARs without affecting dose 
coverage in PTV. 
3.4 Dose prescription 
All plans were optimized to deliver 50.4 Gy in 28 fractions (1.8Gy per fraction). All the plans 
were normalized to the mean of PTV union (PTV union mean=100%). 
3.5 Treatment planning 
All treatment planning was performed on Eclipse treatment planning system (Varian medical 
systems, Palo Alto, CA). The PTV dose coverage criteria were set to D98%≥95% (at least 
98% of the volume should receive 95% of the prescribed dose). The 3D volume element 
(voxel) size was isotropic 2.5mm. In case of reduced CTV-PTV margins, extra helping 
structures were re-defined for OARs due to the possibility of sparing larger volume of the 
normal organs. Example of the bladder, rectum and bowel sparing from high dose of PTV 
were shown below in the figures 30(a, b), 31(a, b), 32(a, b). 
 
 
Figure 30a: (Left) The bladder (yellow) using helping structure bladder-PTV (orange) in case of clinical CTV-PTV 
margins. Figure 30b: (Right) Larger volume of bladder due to the reduced CTV-PTV margins and hence, smaller 
PTV union volume. Image taken from own work. 
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Figure 31a: (Left) Illustration of rectum (cyan) sparing with clinical margins. Rectum-PTV volume with clinical 
margins is shown in purple color. Figure 31b: (Right) Illustration of rectum (cyan) sparing with reduced margins. 
Rectum-PTV volume with reduced margins is shown in purple color. Much larger volume of rectum is spared with 
reduced margins. Image taken from own work. 
 
 
 
Figure 32a: (Left) Illustration of the bowel (brown) sparing with clinical margins. Bowel-PTV with clinical margins is 
shown in dark green color. Figure 32b: (Right) Illustration of the bowel (brown) sparing with reduced margins. 
Bowel-PTV with reduced margins is shown in light green color. Image taken from own work. 
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Treatment planning was done based upon the procedure from Oslo University Hospital (85). 
In table 2 the treatment aims used for both IMRT and IMPT planning are listed. 
Table 2 Treatment planning aims for IMRT and IMPT 
Volumes Treatment planning aims 
PTV Union D98%<95% 
Outer body D2cc<107% 
Rectum As low as possible, but not at the expense of the target volume 
Small Bowel By plotting the entire peritoneal space:volume receiving more than 45Gy should be 
as small as possible. QUANTEC provide less than 195cc. This may be difficult to 
achieve, by experience 45Gy is often given to about 300cc  
Bladder As low as possible, but not at the expense of the target volume 
Sigmoid As low as possible, but not at the expense of the target volume 
Medulla 50Gy 
Cauda equina 60Gy 
Kidneys As low as possible, but not at the expense of target volume. Dose volume 
requirements for each kidney: 
V12<55% 
V20<32% 
V23<30% 
V28%<20% 
Desirable lower dose if possible due to concomitant chemotherapy. 
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During optimization of IMRT and IMPT, some of the treatment planning dose objectives and 
constraints were selected and assigned for target volumes and OARs for all the patients. Table 
2 shows some of the common dose objectives used during optimization to achieve treatment 
aims mentioned in table 3. Lower and upper objectives were declared depending upon the 
required dose distribution over the corresponding volumes. Lower objective for CTV central 
was defined to cover 100% of the volume with at least 50.4 Gy (100% of prescription dose). 
To ensure a homogenous dose in PTV union, lower and upper objectives were demanded to 
cover 100% volume with at least 50Gy and 0% of the volume should not receive dose greater 
than 51.2 Gy respectively. Lower objective to the target volume determines minimum dose, 
while upper objectives were subjected to limit the maximum dose to the PTV. Of note was the 
fact that for PTV union, lower and upper objectives were set at 50 and 51.2 Gy respectively 
instead of ideal 50.4 Gy because an ideal dose of 50.4 Gy would be difficult to achieve.   
For organs at risk, upper objectives were assigned to 0% of the volume should not receive 
dose greater than 50.4Gy. Therefore, upper objective are considered important to limit the 
maximum dose in OARs and thus, the side-effects of the treatment. Weighting factors were 
selected depending upon the priorities assigned to the target volumes and organs at risk during 
optimization of the treatment plan. 
 
Table 3 Treatment planning dose objectives and organs at risk constraints 
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3.5.1 IMRT planning 
For each of the patient, IMRT planning was based on seven equally spaced coplanar 
isocentric 15MV beams ( 0°, 51°, 103°, 154°, 206°, 257°, 308°) with 3° collimator angle for 
each field (20). IMRT plans were constructed with the collapsed cone algorithm. Sliding 
window IMRT delivery technique was used. The IMRT normal tissue constraints included the 
body, bladder, bowel, rectum, sigmoideum, pelvic bone, cauda equine, Medulla, left and right 
kidney. PTV was expanded with a margin of 4-5cm.The dose-volume constraints for this 
volume minus the PTV were assigned to avoid hot spots. An appropriate margin of 4-5mm 
was laid down around the PTV with the intention that the steep dose gradient caused by dose–
volume constraints in PTV expansion minus the PTV will not interfere with the PTV dose 
coverage. All plans were constructed using normal tissue optimization settings: 0.3cm 
distance from target border, 105% start dose, 60% end dose and fall off at 0.6cm with priority 
of 60-70. During optimization process, smoothing factor of 60 was used for both X and Y 
jaws in all the seven fields. The beam placement and dose-volume constraints were selected, 
monitored and optimized if needed to maximize the dose uniformity in the PTV while 
minimizing the dose delivered to the OARs. Quantitatively, all the plans were evaluated by 
analyzing the dose- volume histograms (DVHs) and qualitatively by inspecting isodose 
distribution on each CT slice.  
3.5.2 IMPT planning 
For the proton radiotherapy, IMPT planning was based on modulated pencil beam scanning 
technique utilizing proton convolution superposition algorithm (version11.0.30). Multi-field 
optimization was achieved by simultaneously tuning spot energy and spot weights of each 
pencil beam from all the irradiating fields. The nominal beam energies available were 70-
250Mev. IMPT planning was based on three fields: two lateral opposed fields (90° and 270°) 
and one posterior-anterior (PA 180°) field, to achieve conformal dose distribution in the PTV 
while sparing normal structures. Therefore, appropriate gantry angles were selected to identify 
the best geometrical setting for the respective tumour configuration to avoid as much as 
possible proximal entrance dose through OARs or to minimize the areas of the fields directly 
abutting against them at the distal edge. For patients receiving para-aortic treatment, the size 
of the field required was 40cm in S-I direction whereas the available field size of 40X30cm in 
diameter did not allow treating both PTVs simultaneously. Alternatively, the collimator was 
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rotated 90° to cover the treatment area but an unexpected machine error appeared. Therefore, 
split field technique was used because of the technical limitations of the proton modality. 
Range uncertainties due to HU-stopping power and energy uncertainties were handled by 
treatment planning system parameter by adding 0.5cm axial proximal/distal margin to cover 
the target proximally and distally, respectively whereas set-up uncertainties were included in 
CTV-PTV margins. Spot spacing was set at 5mm and circular lateral target margin of 5 mm. 
Post processing of all the scanned spots was generated by calculating fluence map of each 
field and finally the dose calculation was done by combining all the scanning layers.  
A total dose of 50.4 cobalt grey equivalent (CGE) with 1.8 CGE per fraction was prescribed 
and delivered, assuming a generic relative biological effectiveness (RBE) of 1.1 (72). Beam 
positioning and beam weight optimization was done by inverse planning optimization 
algorithm to avoid the hot spots at the junction between pelvic and para-aortic fields. 
3.6 Evaluation criteria 
The evaluation criteria’s were the same for IMRT and IMPT treatment modalities. Dose-
volume histograms were analyzed for the PTV, Outer body, bowel, bladder, rectum, 
sigmoideum, pelvic bone, Medulla, left and right kidney. The acceptability of the optimum 
treatment plan was based on PTV dose coverage criteria D98%≥95% of the prescribed dose. 
The ratio of the DVH parameters between IMRT and IMPT were calculated. 
Mean organ dose “Dmean” was calculated for all organs at risk for each patient. V10, V30 and 
V45 were calculated from DVHs for all organs at risk and compared with ideal dose-volume 
objectives. Additionally, V45cc was calculated for bowel as per QUANTEC recommendation.  
For the PTV coverage, D98% and D2% were calculated. For the treated volume, V95% was also 
calculated.  
As per Kataria et al, dose homogeneity index (DHI) is a good indicator of the quality of a 
treatment plan, but still analysis of DVH parameters and isodose distributions section–by-
section in CT image remains as a primary way to evaluate treatment plans. DHI should only 
be used as a secondary option once the satisfactory treatment plan has been finalized (90). 
Therefore, isodose distributions of the optimal plans were qualitatively analyzed for PTV and 
OARs at different dose levels in this study.  Additionally, dose conformity index and dose 
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homogeneity index were calculated to cross verify the finalized treatment plan. The following 
formulae were used for the respective analysis: DCI = V95/VPTV and DHI = (D2%-D98%)/Dmean.  
In order to find the hot spots, clinical maximum dose to 2cc of the outer body was calculated 
for each treatment plan and it should not be more than 107% of the prescribed dose. Student’s 
t-test was done for all statistical comparison between clinical margins and reduced margins 
for both treatment modalities. P value of <0.05 was considered statistically significant. 
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4 Results 
This chapter presents various clinically important dose-volume parameters to compare two 
treatment techniques, IMRT and IMPT, both qualitatively and quantitatively. Additionally, 
the effects of reduced margin on relevant parameters are also mentioned.  
4.1 Dose distributions 
The isodose distribution for the PTV was qualitatively visualized at 50% and 95% isodose 
levels. The analysis was apprehended for IMRT and IMPT, both in case of clinical and 
reduced CTV-PTV margins.    
Figure 33 a, b represents the isodose distribution at 95% isodose level for PTV in an IMRT 
plan for clinical and reduced margins, respectively. In figure 34 a, b represents 95% isodose 
level for PTV in an IMPT plan for clinical and reduced margins, respectively, are shown. 
These figures signify the benefit of utilizing smaller CTV-PTV margins in IMRT and IMPT, 
respectively. Sparing of rectum (orange) and bladder (purple) was achieved for much greater 
volume utilizing smaller margins. Considering the steeper dose gradient and greater 
conformity of IMPT around PTV, IMPT effectively surpasses IMRT in sparing greater 
volume of rectum and bladder.  
 
 
Figure 33: Transverse view of isodose distribution at 95% isodose level for PTV in IMRT. Image on the 
left (a) represents clinical margins and on the right (b) represents reduced margins. 
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Figure 34: Transverse view of isodose distribution in IMPT at 95% isodose level. Image on the left (a) 
shows PTV (blue) coverage for clinical margins and on the right (b) shows the PTV (dark blue) coverage 
for reduced margins. 
  
Dose distribution at 50% isodose level in IMRT and IMPT, respectively can be seen in figure 
35 and 36 
 
 
Figure 35: Transverse view of isodose distribution at 50% isodose level in IMRT. Left image (a): 50% 
dose distribution in IMRT with clinical margins. Right Image (b): 50% dose distribution in IMRT with 
reduced margins. 
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Figure 36: Transverse view of isodose distribution at 50% isodose level in IMPT. Left image (a): 50% dose 
coverage in IMPT with clinical margins. Right image (b): 50% dose coverage in IMPT with reduced 
margins.  
 
DVH curves can be seen for IMRT and IMPT, with both clinical and reduced margins, 
respectively in figure 37 and 38. Substantial sparing of rectum, sigmoid and bladder can be 
visualized with reduced margins for both modalities.  
 
Figure 37: Example of DVH for a para-aortic patient for IMRT plans. ∆ represents dose volume parameters for 
reduced margins whereas □ represents clinical margins. Light green, sky blue, yellow represents sigmoid, rectum and 
bladder, respectively 
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Figure 38: Example of DVH for a para-aortic patient for IMPT plans. ∆ represents dose volume parameters for 
reduced margins whereas □ represents clinical margins. Light green, sky blue, yellow represents sigmoid, rectum and 
bladder, respectively 
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4.2 Dose-volume parameters for PTV 
Concerning PTV coverage, table 4 quantifies the differences between IMRT and IMPT for 
clinical and reduced margins. 
Table 4 Various parameters to describe dose coverage in PTV are tabulated for IMRT and IMPT, with clinical and 
reduced margins. All parameters are specified with their mean value ± standard deviation. 
                           Clinical margins (N=10)                      Reduced margins (N=10) 
PTV IMRT   IMPT   IMRT   IMPT   
Mean±SD P-value Mean±SD Ratio Mean±SD P-value Mean±SD Ratio 
D98% 95.5±0.4 <0.01 96.8±0.3 0.99 95.3±0.3 <0.01 96.5±0.5 0.99 
D2% 103.2±0.3 <0.01 101.7±0.2 1.01 103.3±0.5 <0.01 102.0±0.5 1.01 
D2cc (%) 104.4±0.8 <0.01 103.7±0.9 1.00 104.9±0.5 <0.01 104.0±1.1 1.00 
DHI 0.07±0.0 <0.01 0.04±0.00 1.58 0.07±0.00 <0.01 0.05±0.00 1.46 
DCI 0.98±0.0 <0.01 0.99±0.0 0.99 0.98±0.0 <0.01 0.99±0.0 0.99 
 
Treatment plans from IMRT and IMPT were clinically well accepted with, D98%≥95% of the 
prescribed dose. Precisely, D98% of PTV was 96.8% and 95.5% with IMPT and IMRT, 
respectively, for clinical margins whereas D98% of PTV was 96.5% and 95.3% with IMPT and 
IMRT, respectively for reduced margins. The dosimetric gain achieved by using smaller 
margins as compare to clinical margins between IMRT and IMPT can be estimated by ratio 
between IMRT and IMPT. Specifically, the ratio of the D98% for IMRT and IMPT was found 
consistent with both clinical and reduced margins. Concisely, the ratio was 0.99 with 
statistical significance of p-value<0.01. This indicates that the IMPT provides slightly 
superior dose to 98% of the PTV relative to IMRT. However, this small variation in mean 
values is not clinically significant, in case of both types of margins (table 4). 
D2%, clinical maximum dose to PTV was reported with an average of 103.2% and 101.7% 
with IMRT and IMPT, respectively for clinical margins. For reduced margins, an average of 
103.3% and 102% with IMRT and IMPT respectively was achieved. It can be noticed from 
table 4 that D2% with IMPT is relatively less than IMRT for both types of margins but the 
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average difference between two is minimal with statistically significance of  p-value<0.01. 
Therefore, these small differences will not be considered clinically important. Alike D98%, no 
dosimetric gain has been seen utilizing smaller margins as compare to clinical margins with a 
consistent ratio of 1.01.  
Referring to table 4, in context of dose homogeneity and conformity, DHI has an average of 
0.07 and 0.04 with IMRT and IMPT, respectively for clinical margins. For reduced margins, 
DHI has an average of 0.07 and 0.05 with IMRT and IMPT, respectively. Therefore, IMPT 
has proved competency in better homogeneity around PTV as comparative to IMRT, both 
with clinical and reduced margins. DHI has shown a statistically significance of p-value<0.01. 
Although, there exists a small variation in their mean values but it is clinically relevant. 
Likewise, IMPT has evidently provided better dose conformity around PTV as against IMRT 
with both clinical and reduced margins. The difference between the mean values of IMRT and 
IMPT is very small but it has shown a statistically significance of p-value <0.01. However, 
such a small difference between their mean values for IMRT and IMPT is not clinically 
significant. Similar ratio of 0.99 was achieved resulting in no dosimetric gain between clinical 
and reduced margins. Overall, IMPT oversteps IMRT with respect to dose homogeneity and 
conformity around PTV.  
For the hot spots, D2cc in the outer body was calculated for IMRT as well as IMPT. Clinical 
maximum dose (D2cc) to outer body is well under the limit of 107% of the prescribed dose for 
both clinical and reduced margins. Similar IMRT/IMPT dose-ratio was obtained for both 
clinical and reduced margins. IMPT was seen comparatively efficient in delivering low hot 
spots than IMRT (refer to table 4). Precisely, IMPT has kept maximum dose at an average of 
103.7% and 104.0% with clinical and reduced margins, respectively.  
4.3 Dose-volume parameters for organs at risk  
4.3.1 Clinical margins 
In case of clinical margins, sparing of various OARs with IMRT and IMPT at different dose 
levels are reported in table 5 below. The ratio is above 1 for all the parameters, i.e. IMPT 
demonstrated better sparing of OARs compared to IMRT. However, statistical significant 
differences are seen for many dose-volume parameters. 
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Table 5 Various dose-volume parameters are tabulated below to compare sparing of different OARs for IMRT and 
IMPT with clinical margins. All the parameters are specified as mean value± standard deviation.   
*  Para-aortic Patients (N=5) 
 
Rectum sparing 
For V30, IMPT and IMRT have achieved an average of 79.7% and 95.9%, respectively. The 
ratio of 1.20 was seen, with a statistical significance level of p-value <0.01. For V45, an 
average of 77.8% and 63.1% was achieved with IMRT and IMPT, respectively as seen in 
table 5. The dosimetric differences between IMRT and IMPT are considerably large, with a 
statistically significant ratio of 1.23. For Dmean, IMRT has achieved an average of 92.0% 
whereas IMPT has obtained an average of 81.9%, respectively. The ratio between IMRT and 
OARs       IMRT       IMPT  
 Parameters Mean SD P value Mean SD Ratio 
Rectum V30 95.9±4.5 <0.01 79.7±14.3 1.20 
V45 77.8±10.2 <0.01 63.1±16.3 1.23 
Dmean 92.0±3.5 <0.01 81.9±10.3 1.12 
Bladder V30 86.4±11.4 <0.01 62.9±17.6 1.37 
V45 60.3 18.2 <0.01 50.1 20.6 1.20 
Dmean 85.0±7.9 <0.01 66.3±15.3 1.28 
Sigmoid V30 94.6±14.4 <0.01 76.6±23.0 1.24 
V45  79.3 17.5 <0.01 62.9 26.9 1.26 
Dmean 91.9±8.8 <0.01 78.9±19.3 1.17 
Bowel V10 80.1 10.5 <0.01 39.5 15.1 2.02 
V30 39.0 8.7 <0.01 20.4 8.7 1.91 
V45 17.1 6.8 <0.01 12.8 6.2 1.33 
V45 (cc) 404.2 123.70 <0.01 298.5 110.50 1.35 
Dmean 50.6±6.2 <0.05 34.2±26.8 1.48 
Pelvic Bone V10 79.8 8.3 <0.01 65.1 11.1 1.22 
V30  47.8 7.8 <0.01 27.3 5.2 1.75 
V45 15.0 3.5 <0.01 12.7 3.5 1.18 
Dmean 53.9±6.27 <0.01 38.8±5.7 1.39 
Left Kidney* V10 55.5±20.5 <0.01 4.9±9.7 11.33 
V30 2.1±4.1   0.15 0.7±1.3 3.24 
Dmean 24.1±7.8 <0.01 3.5±4.4 6.81 
Right Kidney* V10 57.7±29.8 <0.01 8.0±9.6 7.23 
V30 3.5±6.3   0.24 2.0±2.3 1.78 
Dmean 25.1±10.0 <0.01 6.0±5.5 4.16 
Medulla* Dmax 51.7±5.3 <0.01 40.3±5.5 1.28 
Dmean 31.4±9.4 <0.01 18.3±5.7 1.72 
Cauda equina Dmax 56.9±4.7 <0.01 44.3±11.2 1.28 
Outer body V10 44.9 10.0 <0.01 24.7 5.6 1.82 
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IMPT was 1.12, with a statistical significance of p-value <0.01. Therefore, IMPT plans have 
confirmed superior ability in sparing rectum at V30, V45 and Dmean. 
Bladder sparing 
As seen from table 5, IMRT and IMPT have achieved V30, V45 with an average of 86.4%, 
60.3% and 62.9%, 50.1%, respectively. IMPT has shown consistent pattern in sparing bladder 
to much greater extent relative to IMRT. IMPT has proven its capability in sparing bladder at 
both V30 and V45. The ratio utilizing IMPT as compared to IMRT at V30 and V45 was 1.37 and 
1.20, respectively with a statistical significance of p-value <0.01. 
Also, Dmean was well achieved by IMPT with an average of 66.3% whereas IMRT has 
obtained 85%, respectively. It can be seen from table 5 that the dosimetric gain between 
IMRT and IMPT was 1.28, with a statistically significance of p-value <0.01. Overall, IMPT 
has demonstrated better sparing at V30, V45 and Dmean for bladder.  
Sigmoid and Bowel sparing 
As seen from table 5, V30 was achieved at an average of 94.6% and 76.6% with IMRT and 
IMPT, respectively. The dosimetric gain of 1.24 was seen between IMRT and IMPT, with a 
statistical significance of p-value <0.01. Similarly, V45 for sigmoid was well spared with an 
average of 62.9% by IMPT as compare with an average of 79.3% by IMRT. The statistically 
significant ratio of dosimetric gain was 1.26 for V45. Also, Dmean was achieved at 91.9% and 
78.9% with IMRT and IMPT, respectively. The ratio obtained was 1.17, with a statistical 
significance of p-value <0.01. The above mentioned results clearly signify better sparing by 
IMPT as compare to IMRT at V30, V45 and Dmean for sigmoid. 
On the other hand for bowel, IMRT has achieved 80.1%, 39.0%, 17.1% whereas IMPT has 
obtained 39.5%, 20.4%, 12.8% at V10, V30 and V45, respectively. Evidently, the ratio between 
IMRT and IMPT was 2.02, 1.91 and 1.33 for V10, V30 and V45, with a statistical significance 
of p-value<0.01 for all dose levels, correspondingly. Dmean was achieved at 50.6% and 34.2% 
with IMRT and IMPT, correspondingly. However, a slightly less significant gain was seen 
between IMRT and IMPT. The results mentioned above indicate that IMPT has significant 
spared bowel at all dose levels. 
As per QUANTEC recommendation for bowel in section 2.6.3, V45 was calculated in cubic 
centimeters (cc). IMRT and IMPT have achieved an average of 404.3cc and 298.5cc, 
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respectively. The ratio between IMRT and IMPT was 1.35 which clearly indicates that IMPT 
provides substantially large sparing at V45, with a statistical significance of p-value <0.01.  
Pelvic Bone and Kidney sparing 
The dosimetric advantage of IMPT continues for kidneys at V10, V30 and pelvic bone sparing 
at V10, V30 and V45, respectively. However, a statistically significant sparing was only seen for 
V10 of kidneys and all dose levels of pelvic bone. As IMRT/IMPT dose-ratio was well above 
1 that indicates IMPT is superior in sparing dose to both organs at all above mentioned dose 
levels. Refer to table 5 for quantitative data.  
The same is true at Dmean for both organs. For pelvic bone, IMRT and IMPT have shown an 
average of 53.9% and 38.8%, respectively. The ratio between IMRT and IMPT was 1.39, with 
a statistical significance of p-value <0.01. Similarly, for left and right kidney, an average of 
24.1%, 25.1% was achieved with IMRT whereas IMPT has shown 3.5%, 6.0%, respectively. 
The ratio between IMRT and IMPT was 6.81 and 4.16 for left and right kidney, respectively. 
A statistical significance of p-value <0.01 was seen for both kidney.  
Medulla and Cauda Equina 
IMPT has shown greater sparing at D max for medulla with 40.3% as compare to IMRT with 
51.7%. The statistical significance of p-value<0.01 was seen in table 5. Moreover, both IMRT 
and IMPT have well achieved Dmax under the limit of Dmax<50Gy as pointed out in section 
2.6.6.  Dmean was seen at 31.4% by IMRT and 18.3% by IMPT, with a dosimetric gain of 1.72. 
A statistical significance of p-value <0.01 was also seen.  
Dmax for cauda equina, IMPT has shown better sparing at Dmax with 44.3% as compare to 
56.9% by IMRT. The ratio was 1.28 between IMRT and IMPT, with statistical significance of 
p-value<0.01. IMPT showcased substantially better sparing at Dmax. Moreover, IMRT and 
IMPT both has achieved the Dmax<60Gy as stated in section 2.6.7. 
Outer body, V10 sparing 
V10 for outer body was calculated. An average of 44.9% and 24.7% was achieved with IMRT 
and IMPT, respectively. The ratio of 1.82 was calculated between IMRT and IMPT, with a 
statistical significance of p-value <0.01 as seen in table 5.  
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4.3.2 Reduced margins 
The effects of reduced margin on the sparing of OARs at different parameters between IMRT 
and IMPT are listed in table 6. The ratio is above 1, i.e. IMPT has shown better sparing for all 
OARs at different parameters than IMRT. However, statistical significant dosimetric 
differences are seen for many parameters. 
Concerning the reduced margins, table 6 shows the increased differences between IMRT and 
IMPT at V30, V45 of rectum and bladder, V10, V30 of bowel, V10 of pelvic bone as compare to 
the results from clinical margins in table 5. For V30, V45 of sigmoid and V45 of bowel 
however, less changes in the IMRT to IMPT dose-ratio was found when reducing CTV-PTV 
margins relative to the results from clinical margins in table 5. Also, the same effects were 
seen for V10 of the both kidney, V30, V45 of pelvic bone and Dmax in medulla, cauda equina. 
Although, the change in IMRT/IMPT dose-ratio was seen less between clinical and reduced 
margins but a statistical significance of p-value<0.01 was reported. However, these dosimetric 
differences are so small that they were not considered clinically significant.  
For V10 of outer body, a greater dosimetric gain was seen with smaller margins as compared 
to clinical margins, with statistical significance of p-value <0.01. Refer to table 6. 
Table 6 also demonstrates mean dose to OARs achieved with IMRT and IMPT for reduced 
margins. Larger gain in mean dose to rectum, bladder and bowel was achieved with reduced 
margins as compared to clinical margins (p-value <0.01). For sigmoid and pelvic bone, 
smaller difference in the ratio of IMRT/IMPT with reduced margin compared to clinical 
margin was seen but statistically considerable (p-value <0.01). Such a small variation in Dmean 
for sigmoid and pelvic bone was not clinically relevant. In contrast, dosimetric gain decreased 
for kidneys with reduced margins as compared to clinical margins. Also, a slight increase in 
dosimetric gain was seen for medulla with reduced margins as compared to clinical margins.  
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Table 6 Various dose-volume parameters are tabulated below to compare sparing of different organs at risk for 
IMRT and IMPT with reduced margins. All the parameters are specified as mean value± standard deviation 
* Para-aortic Patients (N=5) 
 
4.4 Dose-volume parameters between clinical and 
reduced margins for IMRT 
4.4.1 Dose-volume parameters for PTV 
It can be seen from table 7 that the ratio is 1 or nearly 1 for all the parameters between clinical 
and reduced margins, i.e. no dosimetric gain has been achieved utilizing reduced margins as 
OARs      IMRT      IMPT  
 Parameters Mean SD P value Mean SD Ratio 
Rectum V30 92.8±7.4 <0.01 69.7±16.5 1.33 
V45 63.0±15.4 <0.01 48.3±20.0 1.30 
Dmean 87.1±5.6 <0.01 73.5±12.6 1.18 
Bladder V30 80.5±12.8 <0.01 53.0±19.1 1.52 
V45 49.6 18.1 <0.01 37.8 20.6 1.31 
Dmean 80.4±8.4 <0.01 57.2±16.7 1.40 
Sigmoid V30 93.6±15.0 <0.01 72.8±23.8 1.29 
V45  72.9 18.9 <0.01 57.4 26.5 1.26 
Dmean 89.6±9.7 <0.01 75.5±19.9 1.19 
Bowel V10 80.5 10.6 <0.01 36.7 15.5 2.19 
V30 38.5 8.6 <0.01 18.5 8.3 2.08 
V45 15.6 6.1 <0.01 11.5 6.1 1.35 
V45 (cc) 369.8 109.01 <0.01 269.1 101.8 1.37 
Dmean 50.0±6.3 <0.01 25.6±10.1 1.95 
Pelvic Bone V10 79.0 8.4 <0.01 60.7 9.1 1.30 
V30  46.3 7.6 <0.01 26.6 5.6 1.74 
V45 14.8 3.3 <0.01 12.6 3.0 1.17 
Dmean 53.0±6.2 <0.01 37.5±5.4 1.41 
Left Kidney* V10 57.3±20.4 <0.01 6.5±10.4 8.8 
V30 2.0±3.7   0.15 0.9±1.5 2.26 
Dmean 24.4±7.4 <0.01 4.1±4.9 6.00 
Right Kidney* V10 59.6±30.3 <0.01 9.9±13.6 6.00 
V30 3.3±5.8   0.22 2.1±3.0 1.59 
Dmean 25.4±9.9 <0.01 6.6±6.9 3.83 
Medulla* Dmax 51.8±5.8   0.07 41.5±10.8 1.25 
Dmean 31.1±8.9  <0.05 17.2±8.3 1.80 
Cauda equina Dmax 55.1±5.3  <0.01 41.7±11.3 1.32 
Outer body V10 44.2 10.1  <0.01 23.0 4.5 1.92 
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compare to clinical margins for IMRT. However, statistical significance is seen for many 
dose-volume parameters. 
Table 7 Various dose-volume parameters for PTV are included for clinical and reduced margins. All parameters are 
specified as mean± standard deviation. 
PTV Clinical margins Reduced margins  
Parameters IMRT  IMRT  Ratio P-value 
D98% 95.5±0.4 95.3±0.3 0.99  <0.01 
D2% 103.2±0.3 103.3±0.5 1.00    0.2 
D2cc 104.4±0.8 104.9±0.5 1.00  <0.05 
DHI 0.07±0.0 0.07±0.0 1   0.01 
DCI 0.98±0.0 0.98±0.0 1  <0.1 
 
Referring to table 7, IMRT has achieved D98%≥95% for both clinical and reduced margins. 
Similarly, D2% was also found well under the limit of 107%, for both clinical and reduced 
margins. In terms of dose homogeneity and dose conformity, DHI and DCI have an average 
of 0.07 and 0.98, for both clinical and reduce margins, respectively. Clinical maximum dose, 
D2cc was found to be 104.4% and 104.9% for clinical and reduced margins, respectively. 
D98%, D2cc, DHI and DCI have shown statistical significance level of p-value <0.05 whereas 
D2% has shown statistically non-significant p-value of 0.2. Although, there exists statistical 
significance for most of the parameters between clinical and reduced margins but the mean 
differences are so small, hence they are clinically insignificant.  
4.4.2 Dose-volume parameters for organs at risk 
Sparing of various OARs at different dose levels with IMRT between clinical and reduced 
margins are reported in table 8. The ratio is above 1 for most of the parameters, i.e. reduced 
margins have demonstrated better OARs sparing as compare to clinical margins with IMRT. 
However, statistical significance is seen for many dose-volume parameters. 
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Table 8 Several dose-volume parameters are tabulated below for OARs sparing with IMRT between clinical and 
reduced margins. All the parameters are specified as mean± standard deviation. 
OARs  Clinical margins Reduced margins   
Parameters IMRT  IMRT  Ratio P-value 
Rectum V30 95.9±4.5 92.8±7.4 1.03 <0.01 
V45 77.8±10.2 63.0±15.4 1.23 <0.01 
Dmean 92.0±3.5 87.1±5.6 1.05   0.00 
Bladder V30 86.4±11.4 80.5±12.8 1.07 <0.05 
V45 60.3±18.2 49.6±18.1 1.21 <0.01 
Dmean 85±7.9 80.4±8.4 1.05   0.00 
Sigmoid V30 94.6±14.4 93.6±15.0 1.01 <0.05 
V45 79.3±7.5 72.9±18.9 1.08 <0.01 
Dmean 91.9±8.8 89.6±9.7 1.02 <0.01 
Bowel V10 80.1±10.5 80.5±10.6 0.99    0.3 
V30 39.0±8.7 38.5±8.6 1.01    0.1 
V45 17.1±6.8 15.6±6.1 1.09 <0.01 
V45 (cc) 404.2±123.70 369.8±109.01 1.09 <0.01 
Dmean 50.6±6.2 50.0±6.3 1.01    0.1 
Pelvic Bone V10 79.8±8.3 79.0±8.4 1.01 <0.05 
V30 47.8±7.8 46.3±7.6 1.03  <0.01 
V45 15.0±3.5 14.8±3.3 1.01   0.2 
Dmean 53.9±6.27 53.0±6.2 1.01   0.00 
Left kidney* V10 55.5±20.5 57.3±20.4 0.96   0.07 
V30 2.1±4.1 2.0±3.7 1.05   0.3 
Dmean 24.1±7.8 24.4±7.4 0.98   0.2 
Right 
Kidney* 
V10 57.7±29.8 59.6±30.3 0.96  <0.05 
V30 3.5±6.3 3.3±5.8 1.06   0.2 
Dmean 25.1±10 25.4±9.9 0.98   0.2 
Medulla* Dmax 51.7±5.3 51.8±5.8 0.99   0.4 
Dmean 31.4±9.4 31.1±8.9 1.00   0.2 
Cauda equina Dmax 56.9±4.7 55.1±5.3 1.03 <0.05 
Outer body V10 44.9±10.0 44.2±10.1 1.01 <0.01 
* Para-aortic Patients (N=5) 
 
In table 8, for rectum, V30 was achieved with 92.8% for reduced margins as compared to 
95.9% for clinical margins. The dosimetric gain of 1.03 was seen, with a statistically 
significant p-value of <0.01. For V45, an average of 77.8% and 63.0% was achieved for 
clinical and reduced margins, respectively. The dosimetric gain of 1.23 was seen, with a 
statistical significance level of p-value <0.01. Correspondingly, Dmean was obtained with 
92.0% and 87.1% for clinical and reduced margins, correspondingly. The ratio between 
clinical and reduced margins was 1.05, with a p-value of 0. Similarly for bladder, V30, V45 
with 86.4%, 60.3% and 80.5%, 49.6% were achieved for clinical and reduced margins, 
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respectively. The dosimetric gain between clinical and reduced margins was 1.07 and 1.21 for 
V30 and V45, respectively with a statistical significant p-value of <0.05 and <0.01, 
respectively. For Dmean, an average of 85% and 80.4% was obtained for clinical and reduced 
margins, with a ratio of 1.05, respectively. The statistical significance of p-value 0 was seen. 
Although, V30 and Dmean for rectum and bladder have shown statistical significance but such a 
small variation in mean values was not clinically significant. However, V45 for rectum and 
bladder have shown much greater dosimetric gain utilizing reduced margins compared to 
clinical margins and hence, they are considered clinically significant.  
For sigmoid, V30 was achieved with an average of 94.6% and 93.6% for clinical and reduced 
margins, respectively. The ratio of 1.01 between clinical and reduced margins was seen, with 
a statistical significance of p-value <0.05. For V45 and Dmean, an average of 79.3%, 91.9% and 
72.9%, 89.6% were achieved for clinical and reduced margins, respectively. The dosimetric 
gain was 1.08 and 1.02, with a statistical significance of p-value <0.01, correspondingly. 
Although, V30 and Dmean for sigmoid have ratio above 1 with a statistical significance but this 
small difference in mean values was not clinically significant. However, the dosimetric gain 
at V45 is considered clinically significant. Refer to table 8 for quantitative data.  
For bowel, V10 was achieved with 80.1% and 80.5% whereas for V30, an average of 39% and 
38.5% was obtained for clinical and reduced margins, respectively. The dosimetric gain was 
0.99 and 1.01, with a non-statistical significance. For V45, an average of 17.1% and 15.6% 
was achieved for clinical and reduced margins. The dosimetric gain was 1.09, with a 
statistical significant p-value of <0.01. However, V45 was also calculated in cubic centimeters. 
Correspondingly, an average of 404.2cc and 369.8cc was achieved for clinical and reduced 
margins. The dosimetric gain was 1.09, with a statistical p-value of <0.01. Also, Dmean was 
achieved with 50.6% and 50% for clinical and reduced margins, correspondingly. The ratio 
was 1.01, with a non-statistical significance. Overall, the dosimetric gain at V45 and V45cc are 
considered clinically significant.  
Pelvic bone, V10, V30 was achieved with 79.8%, 47.8% and 79%, 46.3% for clinical and 
reduced margins, respectively. The ratio was found to be 1.01 and 1.03 between clinical and 
reduced margins at V10 and V30, respectively. The statistical significance was seen for both 
parameters with p-value of <0.05 and <0.01. Furthermore, for V45, Dmean were found to be at 
an average of 15%, 53.9% and 14.8%, 53.0% for clinical and reduced margins, respectively. 
The ratio was 1.01 and 1 for V45 and Dmean, correspondingly. However, the statistical 
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significance of p-value 0 was only seen for Dmean. Overall, the results shown above for pelvic 
bone were not clinically significant due to very small average differences between clinical and 
reduced margins, as it can be seen from the ratios mentioned above.  
Referring to table 8 for left and right kidney, V10, Dmean have shown decrease in dosimetric 
gain between clinical and reduced margins. V10 for right kidney has shown a statistical 
significance of p-value <0.05. However, V30 for left and right kidney have achieved a 
dosimetric gain of 1.05 and 1.06, respectively with a statistically non-significance.  
For medulla, Dmax, Dmean have achieved an average of 51.7%, 3.4% and 51.8%, 31.1% for 
clinical and reduced margins, respectively. The statistically non-significant dosimetric gain of 
0.99 and 1 was seen. However for cauda equina, Dmax was achieved with 56.9% and 55.1% 
for clinical and reduced margins, correspondingly. The dosimetric gain of 1.03 was seen, with 
a statistical significance of p-value <0.05. It can be seen from the ratios mentioned above that 
the differences between their mean values were very small and hence, they are not clinically 
significant. Similarly, V10 to outer body was obtained with 44.9% and 44.2% for clinical and 
reduced margins, respectively. The ratio was found to be 1.01, with a statistically significant 
p-value of <0.01. Likewise, V10 to outer body is not clinically significant.  
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5 Discussion 
The aim of this study is to quantify the dosimetric differences between IMRT and IMPT in 
terms of target dose coverage and sparing of OARs. A second aim is to investigate the effects 
of reduced margins as compared to clinically recommended population-based margins on 
target dose coverage and OARs sparing, which supports personalized strategies in adaptive 
radiotherapy. 
There exists a paucity of scientific data for comparison between IMRT and IMPT in cervical 
cancer and the impact of using smaller margins for dosimetric benefits in patients with 
smaller cervix-uterus motion. Therefore, this study will contribute in the development of 
patient-specific adaptive radiotherapy. 
The results in the present study are compared with Georg et al study (20). Their study is the 
only relevant study available in cervical cancer till date for dosimetric comparison as they 
have only used IMPT. However, there exist few differences between two studies. Their study 
involved 1cm isotropic margins and different IMPT field set-up, with one each in A-P and P-
A direction. Also, they have only included para-aortic patients. Moreover, the differences 
specific to each organ will be discussed later in the respective sub-chapter. Therefore, results 
in their study are not directly comparable with our results. 
5.1 PTV 
The clinical acceptability of treatment plans is fulfilled with IMRT and IMPT, for both 
clinical and reduced margins (table 4). For clinical margins, the dosimetric differences 
between IMRT and IMPT have shown no clinical significance. The same is true for reduced 
margins. Similar results were stated by Georg et al for PTV coverage (20). Apparently, it 
indicates that PTV was adequately covered with 95% isodose distribution. Evidently, there is 
no gain obtained with tighter margins as compare to clinical margins since the ratio between 
two was similar. Likewise D98%, there exists no gain in D2% with reduced margins as 
compared to clinical margins. 
Clinical maximum dose, D2cc to outer body was well restricted under the limit of 107% of the 
prescribed dose in all 10 patients (table 4). The same ratio has been found for normal and 
reduced margins which basically mean the gain of IMPT as compared to IMRT for both kinds 
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of margin is the same. In terms of hot spots, IMRT plans result in slightly higher dose in outer 
body than IMPT. It can be explained by the dose deposition properties of photon beams in 
IMRT technique where substantially high dose is deposited in the entrance channel proximal 
to the target volume. 
PTV dose homogeneity was consistently superior with IMPT plans compared to 
corresponding IMRT plans, with clinical and reduced margins. There exists a dosimetric gain 
of utilizing smaller margins compared to clinical margins for DHI. The reason for better 
homogeneity by IMPT can be understood from the D2% of PTV in table 4. As the average 
PTV DVH of IMPT falls sharply past 50.4Gy with IMPT due to sharper dose gradient, 
therefore it results in more homogenous dose to PTV.  However, IMRT has a longer tail 
beyond 50.4Gy due to relatively slower dose gradient. Hence, it results in comparatively less 
homogenous dose to PTV. On the other hand, PTV dose conformity was found superior with 
both IMRT and IMPT, with no clinical relevance between two, for both clinical and reduced 
margins (table 4).  Reasonably, superior conformity around PTV by IMPT is due to sharp 
distal dose fall-off and finite range of proton beams. Georg et al have also stated in their study 
that IMPT has achieved better dose homogeneity with 6 whereas IMRT has obtained 12 (20). 
In contrast to our study, they stated better dose conformity with 1.24 and 1.38 by IMPT and 
IMRT, respectively (20). 
5.2 Bowel 
Bowel is a major site for absorption of nutrients and quite susceptible to gastro-intestinal 
infection (GI). Often during radiotherapy, small bowel is irradiated incidentally. Majority of 
symptoms appears within 3 years post RT. Mal absorption is one of the significant late effects 
of RT but the dose-volume limits are not yet well specified (84). It has been seen from the 
results in table 5 and 6 that V45 is statistical significantly reduced by IMPT as compare to 
IMRT for both clinical and reduced margins. The ratio between IMRT and IMPT was 1.33 
and 1.35 for clinical and reduced margins, respectively. As the ratios 1.33 and 1.35 are more 
or less equal, therefore, no clinically significant dosimetric gain was achieved utilizing 
reduced margins instead of clinical margins at V45. Reduction in CTV-PTV margins has 
caused less impact on bowel sparing at V45 due to less overlapping of bowel with PTV and 
hence, smaller margins has brought no increase in bowel-PTV volume to be spared. The result 
at V45 clearly indicates that IMPT has quite well restricted high dose irradiation to bowel due 
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to its steep distal dose-fall in P-A field. Again it can be seen from table 5 that IMPT has 
demonstrated better sparing of the bowel as compare to IMRT at V10 and, V30, for clinical 
margins. However, with reduced margins much greater sparing was seen by IMPT as compare 
to IMRT at V10, V30 as seen in table 6. The above stated results at V10 and V30 show that the 
sparing of large volume of bowel at V10 and V30 by IMPT owes to the low entrance dose 
characteristics of IMPT. Moreover, the use of P-A field in IMPT has no direct contribution of 
the dose in bowel. The difference in dosimetric gain has been substantially large with reduced 
margins than clinical margins for both V10 and V30.  
The study by Georg D et al and the present study can be compared in terms of bowel sparing 
at the V30, V45 and Dmean dose levels (20). Georg et al obtained 41% and 19% at V30 for the 
small bowel with IMRT and IMPT, respectively. Thus, the ratio obtained was 2.15. 
Comparatively, for the same dose level, our study has shown 39% vs 20.4% and 38.5% vs 
18.5% with IMRT and IMPT for clinical and reduced margins, respectively, with a 
corresponding ratio of 1.91 and 2.08 (table 5 and 6). It can be seen from above that the ratios 
2.15 and 2.08 are not very different and hence, the dosimetric gain at V30 between two studies 
are more or less comparable. However at V45, Georg et al have achieved sparing of bowel 
volume from 13.1% to 2.7% with IMRT and IMPT, respectively. The ratio between IMRT 
and IMPT was 4.85. Comparatively at V45, the present study achieved 17.1%, 15.6% and 
12.8%, 11.5% with IMRT and IMPT for clinical and reduced margins, correspondingly. This 
means a ratio of 1.33 and 1.35. Clearly, Georg et al have achieved far greater extent of sparing 
in their study compare to the results obtained in this study for both clinical and reduced 
margins. Further in this study, Dmean for IMRT was 50.6% (25.5Gy) and 50.0% (25.2Gy) for 
clinical and reduced margins, respectively whereas Georg et al study found Dmean for IMRT of 
27.2Gy. On the other hand for IMPT, this study achieved 34.2% (17.2Gy) and 25.6% 
(12.9Gy) for clinical and reduced margins respectively as compare to 13.4Gy in their study. 
In this study, the ratio between IMRT and IMPT was 1.48 and 1.95 for clinical and reduced 
margins, respectively whereas it was 2.02 in their study. It can be seen from above that the 
ratio 1.95 and 2.02 are not very different and hence, dosimetric gain at Dmean between two 
studies are clinically comparable. 
Overall, much greater clinically significant sparing of the bowel can be seen at V45 in Georg 
et al study as compared to the results achieved in the present study. This difference at V45 
sparing between two studies is primarily due to the different method of delineating bowel 
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volumes as follows: In Georg et al study, the small bowel was formed by delineating 
individual loops (20) whereas in this study, the entire peritoneal cavity was delineated as 
bowel. Secondly, they delineated and analyzed small bowel and colon separately (20) whereas 
this study has analyzed the combination of small bowel and colon as one volume “bowel”. 
For the sake of verification, the volume of bowel in the present study was calculated and 
compared with the volume of small bowel stated in their study. The average volume of small 
bowel was 1127cc in their study whereas an average of 2795cc was found for the bowel in the 
present study. The differences in the delineation of the bowel between two studies can also be 
seen in figure 39 (a, b). These differences between two studies mentioned above are certainly 
expected to influence DVH parameters. Moreover, their study has only involved para-aortic 
irradiation whereas this study has involved half of the patients with only pelvic irradiation. 
 
 
Figure 39: Differences in the delineation of bowel. a) Contouring of the bowel (orange color) as whole peritoneal 
cavity in the present study. Also, small bowel and colon are combined together in one volume as bowel. b) Contouring 
of the bowel (green color) as individual loops. Also, small bowel and colon are delineated and analyzed separately in 
Georg et al study (20).  
 
QUANTEC recommends V45<195cc as this dose limit is associated to acute toxicities (84). 
However, according to dose planning in cervix cancer at Oslo University Hospital, V45<195cc 
may be difficult to achieve and the local procedure recommended V45<300cc and V45<450-
600cc in case of pelvic and pelvic plus para-aortic LN irradiation, respectively. In table 5 and 
6 it is evident that we were able to achieve V45 with 404.2cc, 369.87cc and 298.5cc, 269.1cc 
by IMRT and IMPT for clinical and reduced margins, respectively.  In these tables the V45 for 
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all the 10 patients are averaged, i.e. including both pelvic (N=5) and para-aortic (N=5) 
patients. Since the sparing of bowel by using IMPT most probably will be influenced by 
whether or not the para-aortic region is included, figures for these two groups are found 
separately. For pelvic irradiation, the average V45 achieved by IMRT was 343.5cc and 
306.1cc for clinical and reduced margins, respectively. Whereas the corresponding results 
achieved by IMPT were 249.3 and 221.5. This clearly indicates the benefit of using IMPT as 
compared to IMRT for this group of patients. However, the dosimetric ratio was 1.37 and 
1.38 for clinical and reduced margins, respectively. It indicates no dosimetric gain achieved 
utilizing smaller margins instead of clinical margins.  
Similarly, for pelvic plus para-aortic irradiation, V45 achieved by IMRT was 464.9cc and 
433.5cc with clinical and reduced margins, respectively. On the other hand, the results 
obtained by IMPT were 347.7cc and 316.6cc with clinical and reduced margins, 
correspondingly. A clear-cut difference in V45 was seen with IMPT as compared to IMRT, 
with both types of margin. The ratio was 1.33 and 1.36 between IMRT and IMPT, with 
clinical and reduced margins. Precisely, these ratios are more or less similar as that for pelvic 
patients. Therefore, alike pelvic patients, there exists no dosimetric gain between clinical and 
reduced margins in para-aortic patients. Para-aortic LN irradiation was carried out by 
extended-field IMRT and hence, larger volume of bowel has to be included to adequately 
irradiate the para-aortic LN. For that reason, V45 in para-aortic irradiation is relatively larger 
than the pelvic irradiation alone. As per the dose/volume recommendations stated before, V45 
for bowel in this study are well acceptable. 
5.3 Bladder 
Radiotherapy with or without chemotherapy for pelvic malignancies is associated with 
genitourinary complications. Overall, the incidence of severe late GU toxicities is less than 
10% with cervical cancer patients (91). In this study a reduction in V30 and V45 was achieved 
with IMPT compared to IMRT at a statistical significance level with p-value<0.01(table 5 and 
6), both with clinical and reduced margins. The dosimetric gain, though, was largest for 
reduced margins both for V30 and V45. One reason worth mentioning for the better sparing by 
IMPT is the selection of beam orientation and number of treatment fields during treatment 
planning. In this study, three IMPT fields have been used: two laterally opposed and one 
posterior-anterior whereas for IMRT, seven fields were used to cover the complex and 
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irregular shape of cervical cancer. It is the differences in the dose deposition pattern of 
photons and protons due to their different physical characteristics as already discussed before 
in the sub-chapter for bowel. Therefore, the above mentioned differences justify the reason for 
large volume of bladder receiving low dose for IMRT and greater extent of bladder dose 
sparing by IMPT. 
Another reason for dosimetric gain with reduced margins as compared to clinical margins is 
due to the influence of reduction in CTV-PTV margins centrally on the bladder volume. As 
the bladder is overlapping with the PTV centrally, a decrease in PTV volume will result in the 
increase of bladder-PTV volume. This structure was used in plan optimization and upper 
objectives were assigned to push the dose down to spare maximum of this volume without 
compromising with PTV coverage.  
Results obtained for bladder V30, V45 and Dmean in the present study can be compared to the 
results in the study by Georg et al (20). In our study, V30 for IMRT was shown to be 86.4% 
and 80.5% for clinical and smaller margins, respectively, while the correspondingly figure in 
Georg et al was 76.6%. V30 for IMPT achieved was 62.9% and 53.0% for clinical and reduced 
margins respectively as compare to 58.0% in their study. The dosimetric gain by IMPT 
compared to IMRT was 1.32 in their study while it was 1.37 and 1.52 for clinical and reduced 
margins in our study. Therefore at V30, the present study has showed a slightly higher gain as 
compared to Georg et al. It can be seen from above that for smaller margins, IMPT has 
reduced V30 to 53% compared to 58% in Georg et al study. It can be explained by the 
difference in beam arrangement between the two studies during treatment planning. IMPT 
beam in anterior-posterior direction passes through the bladder to reach the target volume and 
hence, relatively larger volume of bladder was exposed to V30. On the other hand, no IMPT 
beam was used in anterior-posterior direction in the present study and therefore, much larger 
volume of bladder was spared at V30. However at V45, IMRT has shown 60.3% and 49.6% for 
clinical and reduced margins respectively as compared to 33.8% in their study whereas, for 
IMPT the V45 were 50.1% and 37.8% with clinical and reduced margins, correspondingly as 
compared to 27.6% in their study. The ratio of dosimetric gain in their study was 1.22. 
Comparatively, the ratio was 1.20 and 1.31 with clinical and reduced margins in our study. 
Therefore, greater gain was demonstrated with smaller margins in our study. It is to be noted 
that for clinical margins the ratio 1.20 is not very different than 1.22 in their study and hence, 
they are clinically comparable. However, a much greater dosimetric gain was seen with ratio 
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of 1.31 for reduced margins. This difference in dosimetric gain between the two studies can 
be explained by the difference in CTV-PTV margins. The impact of smaller margins on the 
bladder sparing at V45 was already explained in the preceding paragraph. Similarly, Dmean was 
also compared between the two studies. In their study for bladder, Dmean was achieved with 
38.7Gy and 33.6Gy with IMRT and IMPT, respectively and hence, only small improvement 
in Dmean was obtained with IMPT. Referring to table 5 and 6, this study has shown greater 
dosimetric gain for Dmean with both types of margin as compare to the results showed in their 
study.  
It is important to mention that we have used a drinking protocol in our study to minimize the 
inter-fraction and intra-fraction cervix-uterus motion and with increasing bladder filling also 
keeps the bladder outside the treated volume (23, 92). Since the bladder is a highly distensible 
organ a constant volume of bladder is difficult to maintain due to variation in filling, bowel 
filling and respiration (83). Bladder volume is known to have impact on the position of cervix 
and uterus. As already stated before in section 2.6.2, EBRT is often combined with 
chemotherapy and followed by intra-cavitary brachytherapy boost to tumour however, the 
success of this treatment protocol often comes with the risk of small bowel and bladder 
complications.  A constant bladder filling will limit the inter-fraction and intra-fraction 
bladder variation which in turn will limit the variation in cervix-uterus position. Additionally, 
full bladder will push the large volume of bowel outside treatment field (93) and with the 
increasing bladder filling, part of the bladder also moves out of treatment volume (23, 92). 
However, a review study by Jadon et al revealed that no studies have investigated to 
standardize bladder volumes in cervical cancer (22). Moreover, studies on prostate and 
bladder cancer show that constant bladder volume is difficult to maintain due to reduction in 
bladder capacity with treatment course and radiation cystitis (22). A study by Ahmed R et al 
in cervical cancer with 500ml of water intake with the intent to have comfortably full bladder 
verifies the same trend in bladder volume variation with time as in prostate cancer patients 
(94). The study also concluded that the bladder filling affects change in internal target volume 
due to pelvic rotation in prone position. Overall, variation in bladder volume influences the 
cervix and uterine motion. In this study, we have used 300ml of comfortably full bladder 
protocol with the intent to maximize bowel sparing within the treatment field. Constant 
bladder volume limits the variation in cervix-uterus motion and hence, it allows the usage of 
smaller margins as generously larger margin negates the benefit of using conformal radiation 
therapy. Therefore, smaller margins with online image guided CBCT with soft tissue 
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matching will support adaptive radiotherapy to avoid treatment related morbidity and 
avoiding the under dosing of target volume. 
5.4 Rectum and sigmoid  
As seen in table 5 for clinical margins, IMPT managed to minimize the radiation burden on 
rectum at V30 and V45 significantly with p-value<0.01. This is achieved by utilizing rectum-
PTV helping structure during plan optimization. With the effect of reduced CTV-PTV margin 
on rectum sparing, much greater dosimetric differences were seen at V30 and V45 (table 6). It 
can be explained by the increase in the Rectum-PTV help structure volume due to the 
reduction in central CTV-PTV margins (figure 31a, b). It made possible to push the dose 
down to much larger volume of the rectum. Therefore, a larger volume of rectum can be 
spared with IMPT.  
The selection of two opposed lateral fields allows the potential of IMPT in reducing the 
radiation load largely to all OARs. The geometrical placement of posterior-anterior field 
primarily went both through the rectum and sigmoid to reach the PTV. Therefore, reduction in 
CTV-PTV margins centrally has considerable influence on the volume of rectum to be spared. 
The major advantages of reduced margins are seen for rectum and bladder sparing. 
It is important to mention here that protons are highly dependent upon the stopping power of 
different material; proton range is more in air than tissues. Consequently, the presence of air 
in rectum can have an adverse effect on the range of proton beams. As P-A field used in this 
study traverses through the air in rectum and therefore, changes in the rectal air volume may 
affect the proton range. For these reason, it may results either in under dosing of the target 
volume or over dosing of the normal tissues such as bladder. The presence of air in the rectum 
can be seen as black cavity in figure 40a.  
Also seen in table 5 and 6 for sigmoid, IMPT has shown greater sparing than IMRT at V30 
and V45 for both clinical and reduced margins, with statistically significance of p-value <0.01. 
Over and all, the dosimetric difference between clinical and reduced margins were seen the 
same at all dose levels. Therefore, no dosimetric gain was seen with reduced margins 
compared to clinical margins. The impact of reducing CTV-PTV central margin seems less on 
sigmoid. Primarily, majority of sigmoid resides inside the PTV and therefore, pushing the 
dose down will spare sigmoid but at the cost of losing adequate coverage to PTV and hence, a 
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trade-off was made to maximize local tumour control at the planning stage. For that reason, 
the dosimetric gain was not evidently demonstrable with reduced margin relative to clinical 
margins.  
V30, V45 and Dmean for rectum in this study can be compared to the results in the study by 
Georg et al (20). In their study, IMRT and IMPT have achieved V30 of 90% and 82.8%, 
respectively, while the corresponding figures for V45 were 64.1% and 47.3%. The ratio of 
dosimetric gain was 1.08 and 1.35 between IMRT and IMPT at V30 and V45, respectively.  
These results can be compared with the results obtained in this study shown in table 5 and 6. 
It can be well seen that the gain for clinical and reduced margins at V30 in this study is greater 
than the gain obtained in Georg et al study. Oppositely, gain at V45 was higher in their study 
than the present study. Also, the dosimetric gain was 1.11 at Dmean in their study. Comparing 
with results from table 5 and 6 in the present study, no gain was seen in Dmean at clinical 
margins whereas a little higher dosimetric gain was seen at smaller margins. 
The differences in dosimetric gain at the above mentioned dose levels between two studies 
can be explained by the fact that Georg et al has delineated rectal wall (20) whereas in this 
study, whole rectum was delineated. These differences in the delineation of the rectum can be 
seen below in figure 40(a, b). It is important to mention that the contouring of the rectal wall 
is more useful as it is more prone to toxicities rather than the inside volume of rectum as it 
mostly contains air or feces. However, delineation of rectal wall is a complex task and 
requires a lot of time and efforts. Therefore, the whole rectum was used as a substitute in the 
present study. Precisely, the average volume of rectum was 91cc in this study whereas an 
average of 146cc was mentioned for rectal wall in their study. The above mentioned 
differences in the rectal volumes between two studies are expected to influence DVH 
parameters. 
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Figure 40: Differences in the delineation of the rectum. a) Contouring of the whole rectum (sky blue color) in the 
present study. b) Contouring of the rectum wall (two parallel dotted orange lines) in Georg et al study (20).   
5.5 Pelvic bone 
Most of the total body bone marrow reserve is located in pelvic bones. With the recent 
analysis, this approach has been known to effectively increase the local tumour control with 
subsequent increase in acute hematologic toxicities. Low dose irradiation (V10 and V20) of 
pelvic bone has been found to be the significant factor associated with HT toxicity (8, 13). 
Therefore, IMPT seems a logical substitute due to its physical characteristics. In this study, 
V10, V30 and V45 for pelvic bone sparing with IMRT and IMPT, for clinical and reduced 
margins are tabulated in table 5 and 6.  
For IMRT, V10 was 79.8% and 79% for clinical and reduced margins, respectively. Whereas 
for IMPT, V10 was at 65.1% and 60.7% for clinical and reduced margins, correspondingly. It 
is clear from the results that IMPT has significantly spared larger volume of pelvic bone as 
compared to IMRT with p-value <0.01. Possibly, it is the low entrance dose of two opposed 
lateral IMPT fields which resulted in better sparing of pelvic bone at V10. Furthermore, a 
decent dosimetric gain was achieved with reduction in CTV-PTV margins compared to 
clinical margins. Conclusively, it can be said that with the use of IMPT the incidence of acute 
hematologic toxicity can be potentially minimized due to reduction in volume of pelvic bone 
receiving low dose irradiation (V10).  
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IMPT also demonstrated superior sparing at V30 and V45 compared to IMRT, with both 
clinical and reduced margins, as can be seen in table 5 and 6. However, dosimetric gain was 
observed consistently same between clinical and reduced margins.  
It is important to mention that few study have stated to include pelvic bone marrow in the 
optimization process (14, 95). However, a study by Umesh Mahantshetty has reported the use 
to pelvic bone as a surrogate to active bone marrow as it is much easier to delineate pelvic 
bone than pelvic bone marrow cavities (96). Therefore, based upon the above mentioned 
reference, the present study has contoured pelvic bone and used in the optimization of the 
treatment plans. 
5.6 Kidneys 
Referring to table 5 and 6, IMPT has significantly spared V10 for the left and right kidneys as 
compared to IMRT. For normal and reduced margins, IMPT has proved its potential in 
sparing low dose irradiation to kidneys, with statistical significance of p-value<0.01. 
However, a non significant sparing of kidneys was seen at V30 and V45 with IMPT compared 
to IMRT. The dosimetric gain was seen to decrease with reduced margins compared to 
normal margins at all dose ranges.  
Mean kidney dose (Dmean) was found <15Gy and V28Gy<10%, with both normal and reduced 
margins for both modalities. As per dose/volume limits for kidneys mentioned in section 
2.6.6, IMRT and IMPT has performed tremendously well in sparing dose to kidneys.  
Dmean for left and right kidneys can be compared to the results in the study by Georg et al (20). 
In their study for left kidneys, IMRT and IMPT have achieved a Dmean of 17.3Gy and 2.2Gy, 
respectively. The dosimetric gain of 7.86 was seen. Similarly for right kidney, IMRT and 
IMPT have shown a Dmean of 16.9Gy and 1.4Gy, correspondingly, with a dosimetric gain of 
12.07. In the present study for clinical margins, IMRT and IMPT have achieved a Dmean of 
12.1Gy, 12.6Gy and 1.7Gy, 3Gy for left and right kidneys, respectively. The dosimetric gain 
of 7.11 and 4.2 was seen for left and right kidney, correspondingly. It can be seen that the 
ratios of 7.11 and 7.86 for left kidney between the present study and Georg et al study are not 
very different and hence, the respective dosimetric gain are clinically non-significant. 
However for right kidney, a clinically significant dosimetric gain was seen in their study as 
compared to this study.  
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5.7 Medulla and cauda equina 
For clinical margins, Dmean for medulla was found to be 31.4% and 18.3% with IMRT and 
IMPT, respectively. For the reduced margins, the corresponding figures were 31.1% and 
17.2%. Therefore, a non-significant and almost consistent dosimetric gain was observed 
between reduced and clinical margins. 
Moreover, maximum dose (D max) for medulla was reported at <30Gy with both clinical and 
reduced margins for both modalities. Therefore, dose-volume recommendations mentioned in 
section 2.6.6 are well satisfied. No significant dosimetric gain was seen at D max between 
clinical and reduced margins. The results for Dmax in medulla are shown in table 5 and 6.  
From the table 5 and 6, the results for cauda equina at Dmax indicates that both IMRT and 
IMPT have sufficiently achieved the criteria of Dmax<60Gy as mentioned in section 2.6.7. 
5.8 Outer body 
V10 was seen to be higher for IMRT compared to IMPT with both clinical and reduced 
margins in table 5 and 6, respectively. The result indicates that much larger volume of normal 
tissues received 10Gy i.e. low dose irradiation, from IMRT than IMPT. The use of many 
treatment fields in IMRT to spread the low-dose region around the target volume, results in 
over-spilling of low doses to larger volume of surrounding normal tissues. In contrast, proton 
beams in IMPT deposit relatively lesser dose proximally to target volume. 
 V10 of outer body signifies integral dose to normal tissues. Therefore, an increase in V10 to 
outer body means a consequent increase in integral dose to normal tissues. This can be seen as 
a drawback of IMRT. A study by Hall and Wuu has speculated if this lower dose to large 
volume of normal tissues could be prime reason for radiation induced secondary cancer in the 
future (97). The reason entails from the fact that more number of monitoring units needs to be 
delivered in IMRT field delivery and hence, more total body dose due to leakage radiation. 
Secondarily, IMRT employs greater number of fields which irradiates bigger volume of 
normal tissues with low dose irradiation. Both these factors tend to increase the risk of 
secondary radiation induced cancer. IMRT is likely to increase the risk of secondary 
malignancies by 1.75% (97). The introduction of IMPT spot scanning technique has provided 
as an alternative to substantially reduce the risk of second cancers (17). Reasonably, it is due 
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to the less production of neutrons in spot scanning technique which results in less scattered 
dose to patient by a factor of 10 times less than IMRT. A study by Lomax et al also confirmed 
that integral dose to normal tissues can be substantially reduced with protons due to low 
entrance dose channel proximal to target volume (62). 
5.9 Benefits of smaller margins for IMRT 
As already stated before, that the intention of using smaller margins is to keep the normal 
tissue from being irradiated by high dose of radiation. The results shown in the table 8 
quantifies the dosimetric gain obtained with reduced margins as compared to clinical margins 
for IMRT. Generally, OARs can be substantially spared with the reduction in margins. 
In case of IMRT, major dosimetric gain was evidently visible at high dose level (V45) of 
rectum, bladder, sigmoid and bowel with respective ratios of 1.23, 1.21, 1.08 and 1.09. All the 
four OARs have shown statistical significance of p-value<0.01. The dosimetric benefit of 
such a magnitude is of highly clinical significance. The justification for the dosimetric gain at 
V45 with smaller margins for rectum, bladder and sigmoid is explained as follows. It can also 
be seen from D2% in the table 7 that IMRT demonstrated slower dose gradient past 
prescription dose. Therefore, hot spots occurs much deeper in PTV whereas cold spots occurs 
around the periphery of PTV. This explains the fact that dose distribution around the 
periphery of PTV is lower than dose inside the PTV and there exists a much slower dose 
gradient far from the edges of PTV. It concludes that the immediately abutting structures can 
be spared with high dose irradiation with IMRT treatment plans. Since rectum and bladder are 
immediately abutting structures they can be spared at high dose level (V45) due to relatively 
low dose around the edges of PTV. Moreover, the reduction of CTV-PTV margins results in 
the increase of rectum-PTV and bladder-PTV volume to be spared from high dose irradiation. 
Sigmoid falls mostly inside the PTV but reduction in CTV-PTV margins results in the slight 
decrease of sigmoid overlapping with PTV and hence, it could be spared at V45 with gain of 
only 1.08 relative to clinical margins. Bowel falls mostly outside the PTV with only a small 
volume overlapped with PTV and hence, reduction in CTV-PTV margins hardly shown any 
significant increase in bowel-PTV volume to be spared. Therefore, smaller margins has only 
resulted in the dosimetric gain of 1.09 compared to clinical margins. 
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5.10 Adaptive radiotherapy in cervical cancer 
The potential of IMRT and IMPT treatment for the cervical cancer enables highly conformal 
dose distribution around target volume (8, 18). In cervix cancer, target shape and position is 
highly influenced by pelvic organ volume and position changes over time. As a result, 
matching of pelvic anatomy during patient positioning at treatment unit may vary from 
planned pelvic anatomy. Therefore, appropriate CTV-PTV safety margins are employed to 
avoid the risk of target volume under dosing and unnecessary inclusion of normal tissues in 
high dose irradiation. However, highly conformal treatments are more prone to large inter-
fraction organ motion than intra-fraction motion (22). Various studies have confirmed the 
influence of variation in bladder filling, rectum filling and tumour regression are the major 
contributors of change in cervix and uterus shape and position (23, 28). Intra-fraction motion 
of pelvic organs was found less pronounced with a mean of 0.1-3.0 mm but there is no 
predominant direction of intra-fraction movement (24). Uterus moves more than cervix with 
maximum displacement of upto 48mm anterior-posterior in uterine fundus. However, the 
displacement of such a magnitude in uterine fundus was shown in only one study (25). 
Bladder filling was co-related largely with uterine motion with majorly at uterine fundus 
whereas rectal filling has more impact on cervix and vaginal displacement (23, 25). The 
influence of variation in bladder filling on cervix-uterus motion can be seen in figure 1. 
Cervix cancer is known to regress over the treatment course resulting in the shrinkage of 
tumour volume (28) and hence, online image guidance and advanced online treatment 
planning should be utilized to reduce the radiation exposure to normal tissues (98). 
One way to solve the above discussed inter-fraction and intra-fraction cervix-uterine motion is 
to employ generous population based CTV-PTV margins which reduces the risk of target 
under dosing but unnecessarily causes high doses to normal tissues and hence, normal tissue 
toxicity (23-25, 99). This strategy is promising in terms of target dose coverage but negates 
the benefit of using highly conformal treatment strategies. Additionally, it has been 
demonstrated by various studies that impact of bladder filling on inter-fraction cervix-uterine 
deformation and displacement is patient-specific (26, 27). Hence, it varies from patient to 
patient. Figure 2 shows the inter-patient variability in cervix-uterus motion. Therefore, inter-
patient variability of bladder filling limits the benefit of using standard population based 
margins (29).  
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One section of this study involves clinical CTV-PTV margins of 7 mm (L-I), 10 mm (S-I) and 
15 mm (A-P) properly encompass the inter-fraction and intra-fraction internal cervix-uterus 
motion. It has been known from studies that cervix has greater movement in A-P and S-I than 
laterally. Moreover, bladder filling has more impact on movement of uterine fundus in A-P 
and S-I direction with a displacement of 5-40mm in S-I and 0-65mm in A-P direction (26). 
Clearly, the intra-fraction motion of cervix-uterus is larger in A-P and S-I than laterally. Tyagi 
et al has assessed that impact of inter-fraction cervix-uterus motion and confirmed that 15mm 
margins in A-P are not sufficient to cover CTV in 32% of fractions (89). However, the missed 
CTV volume is minimal (4cc) with a maximum missing in uterine fundus. It is important to 
notice that although uterine fundus has shown maximum displacement, this region has 
minimum evidence of any microscopic disease and its inclusion in CTV is a topic of research 
debate at present (22). Thus, the choice of 15mm in A-P, 10mm in S-I and 7mm in L-R is 
well accepted clinically. Moreover, large movements in uterine fundus due to variation in 
bladder filling were seen only among a small percentage of patients. Therefore, it seems 
illogical to use larger margins to accomodate the variation in cervix-uterus for a small 
percentage of patients. Instead, it makes more sense to use smaller margins to benefit larger 
percentage of patients. Few studies have also confirmed that constant bladder filling limits the 
variation in uterine fundus motion (24, 25) and hence, drinking protocol of 300ml of water 
was employed in this study with the intent of comfortably full bladder achievement.  
Alternatively, smaller CTV-PTV margins can be employed to potentially reduce the chances 
of irradiating normal tissue to high doses. But, for patient with large target motion this 
strategy can cause inadequate target dose coverage (100) as seen in figure 41. Therfore, a 
prior knowledge of a pre-treatment established correlation of impact of bladder filling on 
variation in cervix-uterine motion is mandatory. Smaller CTV-PTV margins of 7mm is an 
approach valid only for smaller target motion. Through the optimum utilization of online 
image guiding CBCT with soft tissue matching, smaller CTV-PTV margins can prove as a 
potential strategy in adaptive radiotherapy. Smaller margins can reduce the normal tissues 
involvement while achieving excellent target dose coverage. Keeping all this in mind, in this 
quantitative study all the 10 patients were replanned with smaller (7mm) CTV-PTV central 
margins with the intent to maximize the OARs sparing without compromising dose to the 
CTV. Also, the study has evidently shown the potential differences achieved using smaller 
margins over clinically recommended population based margins for IMRT and IMPT. The 
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dosimetric gain with smaller margins can be seen as a support to adaptive strategies in 
radiotherapy of cervical cancer with the aim to reduce the dose to normal OARs.  
 
 
Figure 41 : Impact of using smaller CTV-PTV margins in case of patients with large target motion results in target 
underdosing as seen above with these planned dose distribution. The bladder and cervix-uterus are shown in green 
and yellow color, respectively. Image source: (31) 
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6 Conclusions 
The goal of this study was to explore if IMPT is potentially better than IMRT in terms of 
target dose coverage and OARs sparing, for clinical margins. Further, the effects of smaller 
margins were investigated as against standard population based margins to quantify the 
dosimetric gain for clinically relevant dose-volume parameters. Moreover, the benefits of 
using smaller margin for IMRT were studied. It is evident from the results of two modalities 
that IMPT has dosimetric advantages in limiting dose to all the OARs over IMRT, for both 
clinical and smaller margins while maintaining excellent target coverage. Low dose to outer 
body was also considerably reduced with IMPT which signifies less integral dose and hence, 
less chances of resulting in radiation induced secondary cancer.  
 With the effect of smaller margins, a clinically significant dosimetric gain was seen for the 
volumes of rectum and bladder. The same is true for bowel but only at low and medium dose 
levels. Sigmoid was seen to be less clinically benefited utilizing smaller margins since it 
mostly resides inside the PTV for larger pelvic malignancies, such as for patients with 
cervical cancer. Importantly, a decent dosimetric gain was also apparent in low dose to outer 
body. A clinically non-significant dosimetric variation was seen for pelvic bone, medulla and 
cauda equina. The dosimetric gain was however reduced for kidneys. 
Considering the fact that IMRT is currently the most available radiotherapy technique 
worldwide, the impact of smaller margins as compare to clinical margins were separately 
investigated for IMRT. The use of smaller margins has brought clinically significant 
reduction, most notably to rectum and bladder, at high dose level. Whereas at the same level, 
a decent dosimetric gain was seen for sigmoid and bowel. These dosimetric benefits of 
employing smaller margins around PTV can prove clinically advantageous to patients with 
smaller organ motion. 
Briefly, it can be concluded that IMPT is significantly superior over IMRT in limiting dose to 
the OARs in the treatment of locally advanced cervical cancer. IMPT can be considered as a 
potential substitute for IMRT in improving treatment related side-effects. The use of smaller 
margins have also proved substantially large reduction in dose to rectum and bladder, which 
can contribute in the development of personalized adaptive radiotherapy for cervical cancer 
patients.  
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7 Future scope in research 
One limitation of the present study was the use of smaller number of cervical cancer patients. 
Hence, this study can be taken further with large patient population to identify the dosimetric 
benefits of IMPT compared to IMRT. More studies should involve active spot scanning beam 
delivery technique (IMPT) and explore different field set-ups to add more degree of freedom 
in comparative studies.  
Importantly, the present study has been a dosimetric analyses and not a clinical evaluation. 
While, IMPT does appears to limit the radiation exposure to normal tissues to a greater extend 
but there exists no clear evidence whether this reduction will lead to differences in acute and 
late toxicity. Therefore, more studies should aim towards dose effect based mathematical 
modeling between IMRT and IMPT to estimate TCP and NTCP for the verification of their 
biological impact. Furthermore, long-term clinical follow-up is required to evaluate late 
toxicity in the cervical cancer patients treated with IMPT. Hence, the research community 
should consider it as a topic of future study. 
Additionally, in order to facilitate the clinical implementation of personalized adaptive 
radiotherapy it is crucial to standardize the bladder and rectum filling protocols to minimize 
the variation in cervix-uterus motion. Hence, more research work should be carried out in this 
direction.  
Moreover, the wide spread employment of online image guidance such as 4D CBCT with soft 
tissues matching will anticipate the clinical practice of adaptive radiotherapy.  
Lastly, research initiatives should be taken in determining the impact of air pockets in rectum 
on range uncertainties in IMPT.  
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Appendix 
Raw data 
OAR IMRT IMPT IMRT(X) IMPT(X) 
Rectum(V10)     
Patient 1 100 93.59 100 91.52 
Patient 2 100 95.74 100 88.12 
Patient 3 78.18 96.01 64.58 93.13 
patient 4 100 98.06 97.06 87.72 
Patient 5 100 99.99 100 100 
Patient 6 100 100 100 99.01 
Patient 7 99.89 91.42 98.38 84.34 
Patient 8 99.93 98.79 99.15 97.21 
Patient 9 100 99.68 100 96.74 
Patient 10 99.74 97.38 98.62 96.92 
Mean 97.774 97.066 95.779 93.471 
SD 6.885138908 2.884503423 11.00657829 5.363202712 
Ttest 0.379964479  0.277650684  
Ratio 1.007294006  1.024692151  
 
OAR IMRT IMPT IMRT(X) IMPT(X) 
Rectum(V30)     
Patient 1 100 77.32 100 69.74 
Patient 2 88.44 76.73 80.36 65.39 
Patient 3 93.88 85.56 89.58 77.72 
Patient 4 89.36 69.99 84.01 60.64 
Patient 5 99.91 88.33 99.28 74.2 
Patient 6 100 83.37 99.77 77.32 
Patient 7 93.18 45.9 85.4 32.03 
Patient 8 98.86 97.21 97.72 94.94 
Patient 9 100 80.9 98.47 63.88 
Patient 10 95.73 92.13 93.4 80.72 
Mean 95.936 79.744 92.799 69.658 
SD 4.536146676 14.28294 7.425726227 16.5149 
Ttest 0.001638837  0.000301978  
Ratio 1.203049759  1.332208792  
 
OAR IMRT IMPT IMRT(X) IMPT(X) 
Rectum(V45) 
    patient 1 84.1 64.69 73.2 52.96 
patient 2 65.64 62.64 51.39 47.47 
patient 3 78.19 71.39 64.56 59.38 
patient 4 75.34 54.46 53.57 32.47 
patient 5 79.8 71.09 63.59 44.79 
Patient 6 78.95 62.04 60.58 53.99 
Patient 7 59.85 30.45 39.76 15.14 
Patient 8 97.41 95.65 95.51 92.72 
Patient 9 75.95 56.03 54.19 40.34 
Patient 10 82.37 62.71 73.52 43.91 
Mean 77.76 63.115 62.987 48.317 
SD 10.166 16.28475 15.3538906 19.98835 
ttest 0.000313 
 
0.000455899 
 Ratio 1.232037 
 
1.303619844 
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OAR IMRT IMPT IMRT(X) IMPT(X) 
Bladder(V10) 
    patient 1 100 74.81 100 66.56 
patient 2 100 71.6 100 63.06 
patient 3 100 71.54 100 58.24 
patient 4 100 80.59 100 67.79 
patient 5 100 55 100 51.72 
Patient 6 100 68.75 100 63.07 
Patient 7 100 100 100 100 
Patient 8 100 94.27 100 93.16 
Patient 9 100 80.17 100 74.32 
Patient 10 100 79.63 100 71.43 
Mean 100 77.636 100 70.935 
SD 0 12.77537579 0 15.03223518 
Ttest 0.000181518 
 
8.80818E-05 
 Ratio 1.288062239 
 
1.409741312 
  
OAR IMRT IMPT IMRT(X) IMPT(X) 
Bladder(V30) 
    Patient 1 76.93 52.67 74.29 42.32 
Patient 2 86.52 60.02 77.42 51.43 
Patient 3 81.97 59.92 79.26 44.14 
Patient 4 66.59 50.83 61.82 42.46 
Patient 5 74.05 40.34 70.8 33.84 
Patient 6 93.46 53.42 68.74 42.98 
Patient 7 100 100 100 98.57 
Patient 8 98.96 84.46 97.61 69.56 
Patient 9 87.86 69.34 81.27 60.64 
Patient 10 97.54 57.6 93.78 43.57 
Mean 86.388 62.86 80.499 52.951 
SD 11.41668253 17.56615 12.82736437 19.06641 
Ttest 9.95908E-05 
 
4.00303E-05 
 Ratio 1.374292078 
 
1.520254575 
  
OAR IMRT IMPT IMRT(X) IMPT(X) 
Bladder(V45) 
    Patient 1 47.89 35.03 40.2 26.53 
Patient 2 59.05 49.58 47.82 40.21 
Patient 3 59.55 50.24 48.38 32.79 
Patient 4 40.59 33.44 34.35 22.58 
Patient 5 41.94 29.01 32.9 20.31 
Patient 6 48.65 36.62 33.71 22.14 
Patient 7 99.21 94.5 92.14 86.98 
Patient 8 81.46 73.94 65.04 52.58 
Patient 9 62.18 57.77 54.79 48.05 
Patient 10 62.06 40.96 46.91 26.28 
Mean 60.258 50.109 49.624 37.845 
SD 18.21409 20.58457 18.0713802 20.59012 
Ttest 5.45E-05 
 
8.78606E-06 
 Ratio 1.202538 
 
1.311243229 
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OAR IMRT IMPT IMRT(X) IMPT(X) 
Sigmoideum(V10) 
    Patient 1 100 100 100 100 
Patient 2 100 100 100 99.27 
Patient 3 100 98.26 100 97.25 
Patient 4 100 99.97 100 98.79 
Patient 5 100 94.11 100 93.11 
Patient 6 100 100 100 100 
Patient 7 100 88.55 100 81.76 
Patient 8 100 100 100 100 
Patient 9 100 89.63 100 73.92 
Patient 10 100 47.71 99.9 47.08 
Mean 100 91.823 99.99 89.118 
SD 0 16.13130431 0.031622777 17.27632536 
Ttest 0.071702786 
 
0.038701924 
 Ratio 1.089051763 
 
1.121995556 
  
OAR IMRT IMPT IMRT(X) IMPT(X) 
Sigmoideum(V30) 
    Patient 1 100 100 100 100 
Patient 2 100 84.5 98.99 78.3 
Patient 3 98.11 92.9 95.31 86.05 
Patient 4 94.36 76.11 91.25 70.47 
Patient 5 100 74.14 100 67.26 
Patient 6 100 100 100 100 
Patient 7 100 45.72 99.29 39.51 
Patient 8 100 98.9 100 97.73 
Patient 9 100 53.53 99.44 49.27 
Patient 10 53.97 40.1 51.58 39.5 
Mean 94.644 76.59 93.586 72.809 
SD 14.40399343 22.96096 15.03144423 23.83716 
Ttest 0.007757199 
 
0.005971596 
 Ratio 1.235722679 
 
1.285363073 
  
OAR IMRT IMPT IMRT(X) IMPT(X) 
Sigmoideum(V45) 
    Patient 1 100 96.48 98.39 96.11 
Patient 2 76.58 62.27 58.35 52.94 
Patient 3 83.8 78.55 73.65 70.09 
Patient 4 73.07 45.56 67.6 42.37 
Patient 5 68.19 56.83 63.01 45.1 
Patient 6 98.65 94.36 96.84 82.5 
Patient 7 77.68 25.38 62.78 20.45 
Patient 8 98.5 95.14 97.53 93.82 
Patient 9 74.54 37.85 67.85 35.75 
Patient 10 42.09 36.17 42.79 35.35 
Mean 79.31 62.859 72.879 57.448 
SD 17.54775 26.85214 18.86263882 26.52716 
Ttest 0.006588 
 
0.003209466 
 Ratio 1.261713 
 
1.268608133 
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OAR IMRT IMPT IMRT(X) IMPT(X) 
Bowel(V10) 
    Patient 1 55.77 38.81 56.59 38.08 
Patient 2 76.71 65.27 80.87 59.78 
patient 3 76.13 46.05 70.84 44.35 
patient 4 84.45 29.63 87.72 20.9 
Patient 5 85.45 57.42 84.18 55.83 
Patient 6 83.28 45.75 83.85 45.9 
Patient 7 73.71 15.21 73.41 12.35 
Patient 8 84.03 41.58 87.38 35.28 
Patient 9 94.46 24.39 89.98 20.76 
Patient 10 87.3 31.18 89.64 33.41 
Mean 80.129 39.529 80.446 36.664 
SD 10.49432381 15.11781102 10.60931059 15.46747067 
Ttest 4.51872E-05 
 
2.84308E-05 
 Ratio 2.027094032 
 
2.194141392 
  
OAR IMRT IMPT IMRT(X) IMPT(X) 
Bowel(V30) 
    Patient 1 32.6 16.3 31.02 14.94 
patient 2 45.64 33.28 47.17 30.4 
patient 3 45.5 28.12 44.04 24.29 
patient 4 43.47 13.91 41.18 11.34 
Patient 5 52.23 31.91 51.73 31.02 
Patient 6 32.18 16.75 31.48 16.6 
Patient 7 24.33 7.47 25.02 6.53 
Patient 8 45.53 26.46 45.11 23.24 
Patient 9 36.62 14.88 37.03 12.43 
Patient 10 31.81 15.03 31.57 14.62 
Mean 38.991 20.411 38.535 18.541 
SD 8.718022775 8.77775 8.620921902 8.280262 
Ttest 2.51375E-07 
 
1.0766E-07 
 Ratio 1.910293469 
 
2.078366863 
  
OAR IMRT IMPT IMRT(X) IMPT(X) 
Bowel(V45) 
    Patient 1 16.51 11.79 13.26 10.34 
Patient 2 20.87 18.27 20.53 15.91 
Patient 3 21.24 18.13 19.67 16.18 
Patient 4 18.72 7.45 15.21 6.22 
Patient 5 28.68 22.63 26.61 20.86 
Patient 6 9.99 9.45 9.97 8.96 
Patient 7 7.98 4.2 6.95 3.64 
Patient 8 24.01 18.88 20.78 16.78 
Patient 9 12.02 8.68 12.08 7.64 
Patient 10 10.73 8.64 10.59 8.53 
Mean 17.075 12.812 15.565 11.506 
SD 6.800924 6.155655 6.133221466 5.557916 
Ttest 0.000638 
 
0.000119679 
 Ratio 1.332735 
 
1.352772467 
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OAR IMRT IMPT IMRT(X) IMPT(X) 
Pelvic bone(V10) 
    Patient 1 73.88 65.17 74.38 66.09 
patient 2 70.44 53.35 70.14 49.01 
Patient 3 72.02 65.27 69.06 61.75 
Patient 4 71.3 51.27 71.23 48.18 
patient 5 74.41 59.65 72.97 55.77 
Patient 6 84.81 59.03 83.71 59.28 
Patient 7 86.15 80.14 85.59 76.64 
Patient 8 90.15 84.99 89.7 65.59 
Patient 9 82.85 72.83 81.62 69.95 
Patient 10 92.04 59.5 91.33 55.16 
Mean 79.805 65.12 78.973 60.742 
SD 8.274132717 11.09972572 8.395565033 9.0928211 
Ttest 0.000347708 
 
7.81422E-05 
 Ratio 1.225506757 
 
1.30013829 
  
OAR IMRT IMPT IMRT(X) IMPT(X) 
Pelvic bone(V30) 
    Patient 1 45.29 23.26 44.14 23.48 
patient 2 40.64 23.41 39.41 23.16 
patient 3 40.74 23.78 40.36 23.02 
Patient 4 40.37 24.06 38.3 21.26 
patient 5 44.95 28.05 42.82 27.11 
Patient 6 44.68 21.95 42.35 21.69 
Patient 7 52.32 31.26 51.87 31.93 
Patient 8 64.77 39.24 61.66 36.51 
Patient 9 47.49 29.67 47.46 34.04 
Patient 10 56.22 28 54.56 23.66 
Mean 47.747 27.268 46.293 26.586 
SD 7.887027394 5.247947 7.569393121 5.556582 
Ttest 3.82739E-08 
 
3.47415E-07 
 Ratio 1.751026845 
 
1.741254796 
  
OAR IMRT IMPT IMRT(X) IMPT(X) 
Pelvic bone(V45) 
    Patient 1 14.6 11.01 12.43 11.4 
Patient 2 13.32 11 13.32 11.03 
Patient 3 13.24 11.75 12.64 10.78 
Patient 4 11.72 10.27 14.44 8.17 
Patient 5 16.01 13.98 14.58 13.78 
Patient 6 10.7 10.37 10.44 10.11 
Patient 7 16.56 13.96 17.08 13.77 
Patient 8 23.47 18.99 22.21 18.26 
Patient 9 14.28 12.36 13.93 16.06 
Patient 10 16.44 13.38 16.61 13.05 
Mean 15.034 12.707 14.768 12.641 
SD 3.545003 2.610875 3.262408109 2.981359 
Ttest 7.66E-05 
 
0.008771547 
 Ratio 1.183127 
 
1.168262005 
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Target volume IMRT IMPT IMRT(X) IMPT(X) 
PTVUnion_CT(D98%) 
   Patient 1 96.54 97.38 96.09 97.55 
Patient 2 95.47 96.88 95.47 96.44 
patient 3 95.41 96.18 95.41 96.18 
Patient 4 95.2 96.69 95.19 95.89 
Patient 5 95.3 96.75 95.07 96.43 
Patient 6 95.19 97.14 95.07 96.89 
Patient 7 95.59 96.55 95.24 96.29 
Patient 8 95.58 96.76 95.27 96.6 
Patient 9 95.17 97.01 95.08 96.83 
Patient 10 95.24 96.89 95.16 96.3 
Mean 95.469 96.823 95.305 96.54 
SD 0.40798829 0.328026083 0.308265758 0.462433178 
Ttest 1.20384E-06 
 
1.41971E-06 
 Ratio 0.986015719 
 
0.987207375 
  
PTVUnion_CT(D2%) IMRT IMPT IMRT(X) IMPT(X) 
Patient 1 102.83 101.46 102.6 101.17 
Patient 2 103.46 101.66 103.14 101.75 
Patient 3 103.35 101.87 103.56 101.85 
Patient 4 103.58 101.69 104.21 102.24 
Patient 5 103.326 101.6 103.65 101.76 
Patient 6 102.91 101.6 103.13 101.68 
Patient 7 102.65 101.84 102.94 102.11 
Patient 8 103.18 101.56 102.8 101.72 
Patient 9 103.54 101.65 103.5 103.2 
Patient 10 103 101.95 103.06 102.39 
Mean 103.1826 101.688 103.259 101.987 
SD 0.320909887 0.153101 0.474117894 0.544917 
Ttest 1.95393E-07 
 
2.08746E-05 
 Ratio 1.014697899 
 
1.012472178 
  
DHI IMRT IMPT IMRT(X) IMPT(X) 
Patient 1 -0.0629 -0.0408 -0.0651 -0.0362 
Patient 2 -0.0799 -0.0478 -0.0767 -0.0531 
Patient 3 -0.0794 -0.0569 -0.0815 -0.0567 
Patient 4 -0.0838 -0.05 -0.0902 -0.0635 
Patient 5 -0.08026 -0.0485 -0.0858 -0.0533 
Patient 6 -0.0772 -0.0446 -0.0806 -0.0479 
Patient 7 -0.0706 -0.0529 -0.077 -0.0582 
Patient 8 -0.076 -0.048 -0.0753 -0.0512 
Patient 9 -0.0837 -0.0464 -0.0842 -0.0637 
Patient 10 -0.0776 -0.0506 -0.079 -0.0609 
Mean -0.07714 -0.04865 -0.07954 -0.05447 
SD 0.006297 0.004422 0.006837836 0.008286 
Ttest 7.08E-08 
 
4.84004E-08 
 Ratio 1.585529 
 
1.46025335 
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Bowel IMRT IMPT IMRT(X) IMPT(X) 
V45(cc) 
    Patient 1 324.18 231.72 260.72 203.08 
Patient 2 292.89 256.64 288.24 223.65 
Patient 3 330.1 281.49 305.81 251.09 
Patient 4 330.08 131.07 267.21 109.6 
Patient 5 440.73 345.93 408.65 320.39 
Patient 6 429.19 406.15 429.44 385.33 
Patient 7 519.37 273.49 453.6 237.41 
Patient 8 673.7 529.69 583.5 470.71 
Patient 9 436.44 315.48 438.13 277.59 
Patient 10 266.16 213.8 263.17 212.25 
Mean 404.284 298.546 369.847 269.11 
SD 123.7045806 110.5083 109.0184561 101.808 
Ttest 0.000670334 
 
0.000218716 
 Ratio 1.354176576 
 
1.374333915 
  
Outer body IMRT IMPT IMRT(X) IMPT(X) 
V10 
    Patient 1 39.06 23.98 38.98 23.75 
Patient 2 39.57 25.97 39.21 24.51 
Patient 3 32.7 19.93 31.71 18.57 
Patient 4 31.84 16.82 31.53 15.33 
Patient 5 39.95 23.43 38.29 22.64 
Patient 6 58.26 28.88 57.82 28.54 
Patient 7 46.43 23.09 45.8 21.15 
Patient 8 59.99 37.34 59.92 31.03 
Patient 9 53.99 26.22 52.51 23.99 
Patient 10 46.85 21.3 46.45 20.7 
Mean 44.864 24.696 44.222 23.021 
SD 10.00764619 5.600554 10.0714236 4.549563 
Ttest 1.50875E-06 
 
1.87782E-06 
 Ratio 1.81665047 
 
1.920941749 
  
Outer body IMRT IMPT IMRT(X) IMPT(X) 
D2cm3 
    Patient 1 104.34 103.02 104.14 102.27 
Patient 2 105.12 102.97 104.83 103.01 
patient 3 104.41 104.01 104.81 103.4 
Patient 4 105.35 102.91 105.5 104.4 
Patient 5 105.05 102.95 105.37 103 
Patient 6 104.27 103.57 104.7 104 
Patient 7 103.65 103.77 105.38 104.3 
Patient 8 102.53 104.59 104.3 104 
Patient 9 104.97 103.24 104.74 105.6 
Patient 10 104.61 105.7 105.13 105.47 
Mean 104.43 103.673 104.89 103.945 
SD 0.835557033 0.900383252 0.456970702 1.068417833 
Ttest 0.071770132 
 
0.008237396 
 Ratio 1.007301805 
 
1.009091346 
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OAR IMRT IMPT IMRT(X) IMPT(X) 
Left Kidney (V10) 
    Patient 6 45.48 0 44.76 0 
Patient 7 38.36 0 42.26 0 
Patient 8 76.97 22.09 81.24 23.83 
Patient 9 78.33 2.39 77.97 8.76 
Patient 10 38.11 0 40.41 0 
Mean 55.45 4.896 57.328 6.518 
SD 20.48627223 9.667291761 20.4272727 10.39452837 
Ttest 0.000998243 
 
0.000375516 
 Ratio 11.3255719 
 
8.795335993 
 OAR IMRT IMPT IMRT(X) IMPT(X) 
 
OAR IMRT IMPT IMRT(X) IMPT(X) 
Left Kidney (V30) 
    Patient 6 0 0 0.04 0 
Patient 7 0 0 0 0 
Patient 8 9.42 2.97 8.54 3.49 
Patient 9 0.84 0.33 1.09 1 
Patient 10 0.43 0 0.47 0 
Mean 2.138 0.66 2.028 0.898 
SD 4.085697003 1.299211 3.666683788 1.51229 
Ttest 0.150845737 
 
0.157319552 
 Ratio 3.239393939 
 
2.258351893 
  
OAR IMRT IMPT IMRT(X) IMPT(X) 
Left Kidney (V45) 
    Patient 6 0 0 0 0 
Patient 7 0 0 0 0 
Patient 8 1.49 0.86 1.35 0.96 
Patient 9 0 0 0 0.13 
Patient 10 0 0 0 0 
Mean 0.298 0.172 0.27 0.218 
SD 0.666348 0.384604 0.603738354 0.418593 
ttest 0.18695 
 
0.29352482 
 Ratio 1.732558 
 
1.23853211 
  
OAR IMRT IMPT IMRT(X) IMPT(X) 
Cauda Equina(V10) 
    patient 1 56.7 15.64 57.14 14.45 
patient 2 53.95 31.56 52.31 22.74 
patient 3 37.83 48.32 44.84 14.06 
Patient 4 44.22 21.58 51.64 21.88 
patient 5 50.73 22.95 52.9 25.58 
Patient 6 100 0 100 0 
Patient 7 100 100 100 100 
Patient 8 100 100 100 99.73 
Patient 9 100 100 100 100 
Patient 10 100 88.84 100 61.89 
Mean 74.343 52.889 75.883 46.033 
SD 27.52115592 40.12196252 25.59241209 40.33572804 
Ttest 0.030850668 
 
0.005393011 
 Ratio 1.405642005 
 
1.648447853 
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OAR IMRT IMPT IMRT(X) IMPT(X) 
Right Kidney (V10) 
    Patient 6 11.24 0 12.77 0 
Patient 7 76.53 8.21 80.6 6.62 
Patient 8 89.86 23.78 91.41 33.85 
Patient 9 54.64 0.51 55.81 4.45 
Patient 10 56.37 7.4 57.55 4.77 
Mean 57.728 7.98 59.628 9.938 
SD 29.82655981 9.611329253 30.26750601 13.58660259 
Ttest 0.004204823 
 
0.003921391 
 Ratio 7.234085213 
 
6 
  
OAR IMRT IMPT IMRT(X) IMPT(X) 
Right Kidney (V30) 
    Patient 6 0 0 0 0 
Patient 7 0 2.82 0 2.41 
Patient 8 14.57 5.43 13.36 7.11 
Patient 9 0.13 0 0.23 0 
Patient 10 2.79 1.57 2.78 0.77 
Mean 3.498 1.964 3.274 2.058 
SD 6.30289378 2.270227 5.759243006 2.990664 
Ttest 0.244480666 
 
0.223232519 
 Ratio 1.781059063 
 
1.590864917 
  
OAR IMRT IMPT IMRT(X) IMPT(X) 
Right Kidney (V45) 
    Patient 6 0 0 0 0 
Patient 7 0 1.05 0 0.87 
Patient 8 4.59 1.72 3.76 1.95 
Patient 9 0 0 0 0 
Patient 10 0.18 0.38 0.17 0 
Mean 0.954 0.63 0.786 0.564 
SD 2.03408 0.745117 1.664145426 0.861528 
Ttest 0.325889 
 
0.31900679 
 Ratio 1.514286 
 
1.393617021 
  
OAR IMRT IMPT IMRT(X) IMPT(X) 
Medulla Dmax (%) 
    Patient 6 59.5 42.8 60.4 35.3 
Patient 7 52.5 47.6 54.5 53.3 
Patient 8 52 36.6 50 29 
Patient 9 45 41 45.8 52.3 
Patient 10 49.3 33.6 48.4 37.4 
Mean 51.66 40.32 51.82 41.46 
SD 5.296508284 5.445365002 5.745607018 10.80939406 
ttest 0.007967362 
 
0.077295979 
 Ratio 1.28125 
 
1.249879402 
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V95% IMRT IMPT IMRT(X) IMPT(X) 
Patient 1 1780 1774.09 1641.11 1648.29 
Patient 2 1373.36 1381.35 1264.29 1282.2 
Patient 3 1215.25 1218.41 1100 1103.82 
Patient 4 1368.97 1388.8 1250.91 1259.09 
Patient 5 1290 1297.37 1169.33 1181.36 
Patient 6 1700 1736.13 1583 1641.44 
Patient 7 1928.48 1935.39 1814.52 1826.32 
Patient 8 1883.6 1892.4 1763.12 1775.76 
Patient 9 1625.9 1644.09 1541.31 1562.97 
Patient 10 2230 2257.7 2100 2121.44 
 
 
VPTV cm3 IMRT IMPT IMRT(X) IMPT(X) 
Patient 1 1791 1785.5 1655.2 1655.1 
Patient 2 1393.1 1391.9 1282.2 1269.76 
Patient 3 1234.7 1233.8 1117.5 1117.6 
Patient 4 1393.8 1375.82 1273.6 1273.7 
Patient 5 1311.6 1307.1 1191.8 1191.8 
Patient 6 1730.9 1745.3 1613.2 1652.7 
Patient 7 1954.7 1955.7 1846.5 1847.4 
Patient 8 1910.5 1910 1793.7 1793.7 
Patient 9 1655.4 1655.4 1571.6 1571.7 
Patient 10 2268.5 2273.8 2139.6 2145.4 
 
 
DCI IMRT IMPT IMRT(X) IMPT(X) 
Patient 1 0.993858 0.99361 0.991487434 0.995885 
Patient 2 0.98583 0.99242 0.98603182 1.009797 
Patient 3 0.984247 0.987526 0.984340045 0.98767 
Patient 4 0.982185 1.009434 0.982184359 0.988529 
Patient 5 0.983532 0.992556 0.981146165 0.99124 
Patient 6 0.982148 0.994746 0.981279445 0.993187 
Patient 7 0.986586 0.989615 0.982680747 0.988589 
Patient 8 0.98592 0.990785 0.982951441 0.989998 
Patient 9 0.98218 0.993168 0.980726648 0.994446 
Patient 10 0.983028 0.992919 0.981491868 0.988832 
Mean 0.984951 0.993678 0.983431997 0.992817 
SD 0.003545 0.005924 0.003262023 0.006579 
Ttest 0.002843 
 
0.000401492 
 Ratio 0.991218 
 
0.990546675 
  
 
 
 
119 
 
Dmean 
Bladder Volume Cm3 IMRT % IMPT % IMRT(X) % IMPT(X) % 
Patient 1 430.2 79 58.7 76.4 49.4 
Patient 2 226.8 85.6 62.8 79.4 53.9 
Patient 3 162.4 83.8 63.1 79.9 48.2 
Patient 4 489.2 72.7 59.1 68.5 48.9 
Patient 5 363.3 76.2 44.8 72.9 39.3 
Patient 6 220 84.3 56.3 73.3 46.8 
Patient 7 65.8 98.8 97.9 96.9 95.6 
Patient 8 68.7 94.2 85.6 89.7 74.5 
Patient 9 70 86 71.1 82.5 63.7 
Patient 10 336.3 89 63.4 84.1 51.8 
Mean 243.27 84.96 66.28 80.36 57.21 
SD 
 
7.881652393 15.26374062 8.448168769 16.65148976 
Ttest 
 
6.61869E-05 
 
1.95242E-05 
 Ratio 
 
1.281834641 
 
1.404649537 
  
Bowel Volume Cm3 IMRT IMPT IMRT(X) IMPT(X) 
Patient 1 1964.2 40.4 23 38.8 21.4 
Patient 2 1404.7 52.9 42.5 55 39.6 
Patient 3 1552.8 53.2 34.7 51.2 32.4 
Patient 4 1759.6 53.6 20 53.8 16.6 
Patient 5 1535.8 59.9 106.3 58.4 40.6 
Patient 6 4296.7 47.7 26.8 47.8 26.6 
Patient 7 6517.2 41.6 10.9 41 9.3 
Patient 8 2807.8 55.9 33.1 55.4 29 
Patient 9 3631.7 53.2 21 51.2 17.4 
Patient 10 2480.5 47.2 23.6 47.4 23.5 
Mean 2795.1 50.56 34.19 50 25.64 
SD 
 
6.212746753 26.833 6.32525801 10.08719761 
Ttest 
 
0.026332476 
 
1.66443E-06 
 Ratio 
 
1.478794969 
 
1.950078003 
  
Rectum Volume Cm3 IMRT IMPT IMRT(X) IMPT(X) 
Patient 1 121.1 95 80.6 92.1 74.2 
Patient 2 75.6 87.3 79.9 80.9 70.2 
Patient 3 150.2 91.6 86 86.8 79.3 
Patient 4 26.8 89 75.6 81 65.3 
Patient 5 110.7 93.3 87.8 89.2 76.3 
Patient 6 145 94.2 84.8 89 79.6 
Patient 7 80.7 86.6 57.6 78.7 45.8 
Patient 8 35.5 98 97.5 97 95.2 
Patient 9 102.6 92.9 82.6 87.3 70.6 
Patient 10 61.2 92.5 86.7 88.8 78.6 
Mean 90.94 92.04 81.91 87.08 73.51 
SD 
 
3.54313107 10.34294714 5.580282749 12.60471252 
test 
 
0.001316471 
 
0.000292761 
 Ratio 
 
1.123672323 
 
1.184600735 
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Sigmoideum Volume Cm3 IMRT IMPT IMRT(X) IMPT(X) 
Patient 1 17.6 97.5 98.6 98.1 98.5 
Patient 2 104.9 93.4 84.6 87.8 79.3 
Patient 3 41.5 94.6 91.5 91.6 86.6 
Patient 4 69.4 90.4 78.3 88.2 74.5 
Patient 5 30.9 91.7 76.6 90 71.7 
Patient 6 35.3 98.4 98.3 97.5 95.5 
Patient 7 84 92.8 56.9 88.5 51.6 
Patient 8 20.8 99.2 98.2 99 97.3 
Patient 9 97.9 93.1 63.2 90.9 57.5 
Patient 10 71.2 68.3 42.8 64.7 42.2 
Mean 57.35 91.94 78.9 89.63 75.47 
SD 
 
8.806083756 19.34350307 9.748395879 19.89254746 
test 
 
0.006399872 
 
0.004242516 
 Ratio 
 
1.165272497 
 
1.187624222 
  
Cauda Equina Volume Cm3 IMRT IMPT IMRT(X) IMPT(X) 
Patient 1 18.5 24.5 9.4 24.1 7.6 
Patient 2 18.8 21.6 13.1 20.8 11.5 
Patient 3 14.9 15.7 13.2 17.3 10.7 
Patient 4 13 19.3 9.8 20.8 9.6 
Patient 5 25.1 20.5 8.5 19.4 10.5 
Patient 6 22.1 42.5 9.6 42.8 8.5 
Patient 7 27.7 49.9 37.8 47.9 36.4 
Patient 8 10.6 44.6 43.8 43.5 40.7 
Patient 9 14.4 41 40.5 41.6 51.6 
Patient 10 9.9 43.5 32.1 43.2 29.6 
Mean 17.5 32.31 21.78 32.14 21.67 
SD 
 
13.0185722 14.79082298 12.504417 16.34163395 
Ttest 
 
0.003105454 
 
0.007746804 
 Ratio 
 
1.483471074 
 
1.483156437 
  
Left Kidney Volume Cm3 IMRT IMPT IMRT(X) IMPT(X) 
Patient 1 
     Patient 2 
     Patient 3 
     Patient 4 
     Patient 5 
     Patient 6 129.6 21.3 1.6 21.1 1.6 
Patient 7 287.4 16.4 1.4 17.7 1.2 
Patient 8 146.4 34.7 11.1 34.7 12.1 
Patient 9 141.6 29.7 3.3 29.5 5.1 
Patient 10 191.6 18.5 0.3 18.9 0.3 
Mean 179.32 24.12 3.54 24.38 4.06 
SD 
 
7.781516562 4.360389891 7.384578526 4.850051546 
Ttest 
 
0.00025501 
 
6.83979E-05 
 Ratio 
 
6.813559322 
 
6.004926108 
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Right Kidney Volume Cm3 IMRT IMPT IMRT(X) IMPT(X) 
Patient 1 
     Patient 2 
     Patient 3 
     Patient 4 
     Patient 5 
     Patient 6 127.3 11.7 0.8 11.6 0.8 
Patient 7 349.8 27.5 9.4 28.7 8.5 
Patient 8 113.9 39.5 13.6 38.9 17.8 
Patient 9 155.6 24.2 1 24.5 2.5 
Patient 10 185.2 22.7 5.4 23.1 3.5 
Mean 186.36 25.12 6.04 25.36 6.62 
SD 
 
9.990595578 5.516158083 9.870055724 6.875827223 
test 
 
0.000909254 
 
0.000379913 
 Ratio 
 
4.158940397 
 
3.83081571 
  
Medulla Volume Cm3 IMRT IMPT IMRT(X) IMPT(X) 
Patient 1 
     Patient 2 
     Patient 3 
     Patient 4 
     Patient 5 
     Patient 6 22.4 31.8 14 31.7 11.8 
Patient 7 16.8 16.5 10.9 16.5 12.1 
Patient 8 9.3 41.1 24 39.4 12.7 
Patient 9 14.4 30.5 22.9 31.2 31.2 
Patient 10 7.4 37.2 19.6 36.8 18.2 
Mean 14.06 31.42 18.28 31.12 17.2 
SD 
 
9.363599735 5.669832449 8.872823677 8.252575356 
Ttest 
 
0.004071778 
 
0.025188199 
 Ratio 
 
1.718818381 
 
1.809302326 
  
Pelvic Bone Volume Cm3 IMRT IMPT IMRT(X) IMPT(X) 
Patient 1 1828.8 51.1 35.5 50.5 35.8 
Patient 2 1740.7 47.6 33.1 46.9 32.2 
Patient 3 1262.3 47.9 36.2 46.7 35.4 
Patient 4 1434.4 47.1 33.6 47.1 30.7 
Patient 5 1404.9 50.6 37.7 48.4 36.2 
Patient 6 1753.8 54.3 34.8 53.1 34.5 
Patient 7 2181.4 58.4 45 58 44.6 
Patient 8 1135.9 65.2 51 63.8 45.8 
Patient 9 1708.3 54.9 42.2 54.1 44.4 
Patient 10 1551.7 61.9 39 61.2 35.7 
Mean 1600.22 53.9 38.81 52.98 37.53 
SD 
 
6.269502904 5.70836618 6.229107302 5.400216045 
Ttest 
 
1.23822E-07 
 
9.46416E-07 
 Ratio 
 
1.388817315 
 
1.411670663 
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Doseplanlegging cervix cancer 
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